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INTRODUCTION 
 
 
Extremity sarcomas are rare( less than 1% of all malignancies ) and pose a challenging 
problem for patients and their surgeons /  oncologist. In past, these cancers have treated 
by amputation with relatively  poor functional   outcome.  Over  the last 30 yrs ,  limb  
salvage  has evolved ,  this technique  has been proven safe and effective .  There have 
been developments in several areas to improve the outcomes with limb preservation.  The 
neoadjuvant chemotherapy causes tumour necrosis, which allows for safer removal. In 
addition Chemotherapy causes  the tumour to develop a rind or margin and  in some cases 
Shrink  ,  helping  the  surgeon  to  completely  resect  the  tumour  and   minimize the  
removal of normal tissue. Imaging also play a major role in limb salvage with 
development of radiographic studies  such as  MRI .The surgeon can better see the extent  
of  tumour  and  plan resection precisely.   
 
 Finally, there have been major development in limb reconstruction.  Surgeons now have 
available implants that can be matched to the patients size, stronger metals, bone and soft 
tissues allografts  micro vascular muscular transfer procedure. These techniques allow the 
limb to be resorted with good function.  
 
Despite all of these improvement and enthusiasm for limb salvage , It is not For  
everyone .     There  are  contraindications  and  complications  that need to be 
considered. The decision needs to have a thorough understanding of the advantages and 
disadvantages of limb salvage before pursuing this technique.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
 
 
 
 
 
 
 
 
                                         AIM OF THE STUDY  
 
     This is the era of minimal surgery and maximal functional outcome without     
compromising oncological principles and survival benefit. Before 1990, nearly 
90% of the extremity soft tissue sarcomas were treated by amputation. But after 
1990, about 90% of these tumours are treated by limb sparing surgeries, thanks to 
better understanding the nature of soft tissue tumours, and improvement in micro 
vascular  techniques and development in prosthetic field.  
This is a retrospective analytical study about extremity soft tissue sarcomas in our 
institution for past 5years (2001-2005). This study thoroughly analyze the 
epidemiology, anatomical distribution  , common histological types of soft tissue 
sarcomas in extremities . But main focus of this study is , to analyze the 
proportion of patients underwent limb sparing surgeries, on what basis patients 
were offered either limb sparing procedure or amputations . Since our institute is 
tertiary centre many soft tissue sarcomas are referred with local recurrence due to 
unplanned first surgery, this study mainly analyze the feasibility of limb salvage 
treatment in these patients and the factors adversely affect treatment outcome.  
This study to analyze about local recurrence after multimodality treatment 
especially after limb sparing procedure whether these procedures are 
compromising the oncological  principle and affecting overall survival rate . And 
to analyze about impact of multimodality therapy in saving the patient’s limb. 
Finally, this study analyze about  whether achieving local control has any 
consequence in development of distant metastasis.     
 
 
 
 
 
 
 
 
 
 
 
       LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HISTORICAL REVIEW 
 
 
PAPYRUS EBERS  described cancer as a tumour which is not to be touched as early 
as 1552BC. HIPPOCRATUS (460-375 BC) believed that cancer is incurable and 
described about nasal angiofibroma . GALAN, ALBUCASIS and later ARDRIUE 
(1306AD) refrained from surgery and were pessimistic. With advent of microscope 
KOCHER (1602-1680), LEUWENHOEK (1632-1732) gave description of cell that 
caused diseases. In 1712, EHNULLERUS published a book on of tumours .The term 
‘soft cancers’was introduced by WARDROP(1782-1869) 
 
The credit of differentiating soft cancer from carcinomas must  be given to 
CHARLESBELL (1774-1842) who first described and illustrated soft cancer of thigh 
in 1816. ABERNETHY (1780-1848) gave first classification of sarcomas in 1811 . 
MALHNEY in 1866 wrote the first monograph on fibrous tumours, Between 1860-
1870, most of sarcomas were identified . ADAMS IN 1898 , BORST IN 1902 
classified connective tissue tumour more extensively. In 1910, HARRISION 
introduced tissue culture technique and ROVES in 1911 transferred sarcoma to a 
chicken by inoculating cell free infiltrate. 
 
In classification and morphology of STS the credit belongs to A.P.STOUT who 
attempted to lay the foundation for classification and sub classification of STS as 
early as 1947.  
 
 
 
ETIOLOGY 
GENETIC 
Involvement of genetic factors in the genesis of soft tissue sarcoma is manifest by 
strong hereditary tendency for certain sarcomas (Strong,1977; Littlefield, 1984; Li et 
al, 1988; Rowley, 1988). Gardner’s syndrome is an hereditary disease, one feature of 
which is desmoid tumours (McAdam and Goligher,1970); neurofibromatosis  I also 
features tumour of the soft tissues: neurofirbromas and neurofibrosarcoma. A 
significant proportion of these patients ultimately exhibit transformation of the 
neurofibroma into neurofibrosarcoma (Fraumeni, 1973; Strong, 1977; Zoller et al, 
1977). This disorder is associated with a mutation in the NF1 gene. It has been 
proposed that malignant degeneration reflects the two-hit hypothesis in which one 
allele is constitutionally inactivated in the germline while the other allele undergoes 
somatic inactivation (the second hit)(Colman et al., 1955). Sarcomas of soft tissue 
and bone, particularly osteosarcoma, have been observed later in life in surviving 
patients with familial or bilateral retinoblastoma (Derkinderen et al., 1988 Wong et 
al., 1997). Patients with Li-Fraumeni syndrome often develop sarcomas (Li-Fraumeni 
, 1969; Li et al., 1988). The Li-Fraumeni syndrome is inherited as an autosomal 
recessive trait, and is primarily characterized by soft tissue and bone sarcomas and 
breast cancer; other features include brain tumour, leukemia and adrenocortical 
cancer occurring before the age of 45 (Li and Fraumeni, 1969; Li et al ., 1988). Some 
patients develop multiple malignancies (Hisada et al., 1998). A germline mutation in 
 
 
the p53 tumour suppressor gene is found in most affected families (Malkin, 1993; 
Evans and Lozano, 1997; Varley et al, 1997). 
MOLECULAR BIOLOGY 
       Deletions or mutations of the tumour suppressor retinoblastoma (Rb) gene are 
critical in the pathogenesis of retinoblastoma and a variety of solid tumours. 
Alterations  in the Rb gene are common in soft tissue sarcoma (Cance et al., 1990; 
Wunder et al., 1991; Karpeh et al., 1995), occurring in up to 70 percent of tumours 
(Cance et al., 1990; Karpeh et al., 1995). It has been proposed that Rb alterations are 
primary events in human sarcomas and many be involved in tumorigenesis or the 
early phases of tumour progression Karpeh et al., 1995). The Rb gene is critical for 
proper entry and transition through cell cycle. This change has been shown to be 
associated with infrequent osteogenic or other sarcomas as second malignant 
neoplasm in patients with hereditary retinoblastoma (Friend et  al., 1987). 
Furthermore, the absence of detectable RB protein is associated with a small 
proportion of apparently sporadic sarcomas (Shew et al., 1989). In an examination of 
43 sarcomas of bone and soft tissues, Wunder et al., (1991) found alteration in the RB 
gene in approximately 40 percent of the tumours. 
The gene p53 is also a ‘tumour suppressor gene’ and mutation on this gene and/or 
absence of its protein is associated with the development of sarcomas and other 
malignancies. The p53 protein is a transcriptional activator that plays a key role in the 
integration of signal; inducing cell division, arrest of DNA synthesis following DNA 
damage, and programmed cell death (apoptosis). DNA damage results in increased 
 
 
levels of p53 protein which induces cell cycle arrest at the G1/S interface, thereby 
permitting the cell to repair genomic damage or to initiated apoptosis . 
Somatic mutations in the p53 gene are the most frequently detected molecular 
alteration in sporadic soft tissue sarcoma. These mutations have been detected in a 
variety of soft tissue sarcomas including malignant fibrous histiocytoma(MFH), 
leiomyosarcoma, liposarcoma, and rhabdomyosarcoma . 
The MDM2 gene, located at 12q13-14, is overexpressed in a variety of human 
tunmouirs including soft tissue sarcomas (Oliner et al., 1992, khatuv et ak., 1993; 
Florenes et al., 1994; Nilbert et al., 1994). Its gene product localizes predominantly to 
the nucleus, where it acts as an inhibitor of the p53 tumour suppressor gene product. 
The gene SAS has been observed to be amplified in a high proportion of malignant 
fibrohistocytomas and liposarcomas (Smith et al., 1992). Furthermore, (uda et al., 
1993) reported that approximately 40 percent of sarcomas were found to have an 
increased expression of c-erb-B2 oncogene and epidermal growth factor receptor 
(EGFR). Additional gene mutations or other alterations in sarcomas include: CDK4 
(Kanoe et al., 1998), nrs, myc, and c-fas (Brown et al., 1984; Chardin et al., 1985).  
CYTOGENETICS 
         Most synovial cell sarcomas are characterized by the translocation 
t(x;18)(p11.2q11.2). The breakpoint of this translocation fuses the SVT gene from 
chromosome 18 to one of two homologous genes, SSX1 OR SSX2 on the X 
chromosome (Clark et al., 1994; Kawai et al., 1998). The SVT-SSX gene is thought 
 
 
to function as an aberrant transcriptional regulator. The nature of the chimeric gene 
appears to have prognostic and pathogenetic importance, as metastasis-free survival is 
much higher (relative risk 3.0) with SVT-SSX2 compared to SVT-SSX1 (Kawau et 
ak., 1994). SVT-SSX1 is associated with biphasic tumours (glandular epithelial 
differentiation on a background of spindle tumour cells), while SVT-SSX2 us 
associated with monophasic tumours that lack glandular epithelial differentiation. 
Other chromosomal changes characteristic of specific sarcoma type include the 
reciprocal exchange t(1;22) (q24;q12) seen in approximately 85-90 percent of 
Ewing’s sarcoma and primitive neuroectodermal tumours (PNET) (Turc-Carel et al., 
1988; Landanyl et al., 1990; Delattre et al., 1994). In this translocation, the EWS gene 
from chromosome 22q12 is covalently linked to the ETS family member, FLI -1 
(Zucman et al., 1993). The chimeric proteins that result from this translocation may 
alter transcription of an unidentified gene on chromosome 22 (Delattre et al., 1992; 
Zucman et al., 1993). A less common translocation t(21;22)(a22;q12) has also been 
identified and links to EWS to a different ETS  family member, ERG (Sorensen et al., 
1994). 
Myxoid and round cell subtypes of liposarcomas display a reciprocal translocation 
t(12;16)(q13;p11) (Crozat et al., 1993; Rabbitts et al., 1993). In this translocation, the 
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone; induced by 
DNA damage) gene is inserted adjacent to a novel gene called FUS. The fusion gene, 
called TLS-CHOP, shows sequence homology to the Ewing’s fusion gene (Aman et 
al., 1992; Crizat et al., 1993; Rabbitts et al., 1993; Hisaoka et al., 1998). It falls to 
 
 
induce G1/S arrest, which is one of the functions of the non-oncogenic form of CHOP 
(GADD153)(Barone et al., 1994). Identification of the fusion gene has been used as a 
diagnostic aid for these subtype of liposarcoma (Hisaoka et al.,1998). 
Alveolar rhabdomyosarcomas show a translocation at t(2;13)(q35;q14) or less often 
t(1;13)(p36;q14); the chimeric genes have been cloned and have been termed PAX3-
FKHR and PAX7-FKHR, respectively (Davis and Barr, 1997). PAX7-FKHR tumours 
more often present with extremity lesions, are more likely to be localized, and are less 
likely to metastasize widely than PAX3-FKHR tumours (Kelly et al., 1996b). A 
downstream target of PAX3-FKHR may be MET, which encodes a receptor involved 
in growth and motility signaling (Ginsberg et al., 1998).  
Clear cell sarcoma is usually classified as a malignant melanoma, although 
cytogenetically the tumours are distinct. Clear cell sarcomas often exhibit a 
translocation at t(12;22)(q13-14;q12), which is not seen in malignant melanoma 
(Fletcher, 1992). Trisomy of chromosome 8 is also observed in clear cell sarcoma 
(Travis and Bridge, 1992). Alterations in the 12q13-15 region has been described in a 
subgroup of haemangiopericytomas (Sreekantaiah et al., 1991; Mandahl et al., 1993). 
Multiple chromosomal abnormalities have also been seen in some of these tumours  
(Sreekantaiah et al., 1991). 
 
ENVIRONMENTAL FACTORS 
 
 
 Radiation is recognized as capable of inducing sarcoma of bone and soft tissue. The 
frequency increases with radiation dose and with the post-radiation observation 
period (Kim, 1978; Sadove et al., 1981; Robinson et al., 1988). The most frequent 
histopathological type of radiation-induced sarcoma arising in soft tissues is 
malignant fibrous histiocytoma (approximately 70 percent).Although seen rarely after 
low doses (<40 Gy), this is predominantly a complication of high-dose treatment. The 
actuarial frequency at 15-20 years is approximately 0.5 percent for radiation of 
normal bone and soft tissue in the adult treated with radiation alone to full dose.  
The frequency is higher following treatment of children, especially with radiation and 
chemotherapy; the frequency may be as high as 20-30 percent at remote times . 
Chemotherapeutic agents are likewise associated with risks of sarcoma induction. For 
example, there are two reports that describe the appearance of osteosarcoma in 
children treated for leukaemia by drugs alone (Shaw et al., 1988). Tucker et al, (1987) 
analyzed the late sequels in 9170 long-time survivors of childhood cancer. 
Chemotherapy alone concluded  to be an independent risk factor. 
Exposure to a few selected industrial chemical including vinyl chloride, 
phenoxyacetic acid, arsenic and phenoxyherbicides may be followed by the 
appearance of sarcomas. There are, however, a number of inherent problems in 
occupational epidemiology with small number of patients in any given series and the 
difficulty  in isolating  a single agent (Sathiakumar and Delzell, 1997). For these 
reasons,  few associations can be considered established and causal (Dich et al., 
1997). For example, there is a clear association between vinyl chloride and hepatic 
 
 
angiosarocoma (Lee et al., 1996). Phenoxyacetic acid (Hardell and Eriksson, 1988) 
and arsenic (Lander et al., 1975) are also implicated as inducing agents for hepatic 
sarcomas in humans. Wingren et al (1990) reported an increased incidence of soft 
tissue sarcomas in gardeners (phenoxy herbicides), railroad workers, construction 
workers exposed to impregnating agents or asbestosis and unspecified chemical 
workers. The association between exposure to phenoxy herbicides and soft tissue 
sarcoma has been corroborated (Vineis et al., 1991). The last risk may be greater 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or higher chlorinated dioxins. High 
intensity chlorophenol exposure in jobs involving wood preservation, machinists and 
the use of cutting fluids may increase the risk of soft tissue sarcoma, independent of 
phenoxy herbicides (Wingren et al., 1990; Hoppin et al., 1998). However, some 
studies have not confirmed this association (Hardell and Erikson, 1988). 
Chronic oedema and trauma may also be contributing factors to the malignant 
transformation. Sarcomas of soft tissue (primarily lymphangiosarcomas) may be 
observed following massive and quite protracted oedema. Classically, this has been 
seen in the post-mastectomy, lymphoedematous arm (Stewart-Treves syndrome) 
(Stewart and Treves, 1948; Tomita et al., 1988). It has also been described following 
chronic lymphoedema due to filarial infection (Muller et al., 1987).Chronic irritation 
secondary to foreign bodies may be a factor in the induction of sarcomas. Trauma is 
rarely a factor in the development of these tumours with the exception of desmoid 
tumours.  
 
 
 
CLASSIFICATION 
The  rationale  for  developing  a  well-defined ,  comprehensive  and   flexible 
classification  system of soft tissue tumours is  to provide morphological guidelines 
which  expand our understanding of neoplasia  ,   predict biological  behaviour and 
facilitate the development of more effective treatment.       Originally, classification 
schemes  were  descriptive  in  nature  and  based  on  tumour  cell   configuration. 
Subsequently  they  have  evolved through the concept of  histogenesis  or  ‘cell of 
origin’    to  the current belief  that  a primitive  or   stem-like    mesenchymal cell 
undergoes neoplastic transformation and, depending on the genetic code translated, 
differentiates along one or multiple cell lines. 
 
 
 
SOFT TISSUE SARCOMA- WHO CLASSIFICATION ( MODIFIED) 
1. Fibrous tumours  
2. Fibrohistiocytic tumours 
3. Lipomatous tumours 
4. Smooth muscle tumours 
5. Tumours of blood vessels and lymphatics 
6. Skeletal muscle tumours 
7. Perivascular tumours 
8. Synovial tumours 
9. Mesothelial tumours 
10. Peripheral nerve sheath tumours 
 
 
11. Primitive neuroectodermal tumours 
12. Extraskeletal and cartilaginous tumours 
13. Miscellaneous tumours 
  
         
Currently, the most widely used classification system is the Enzinger and 
Weiss(2001) modification of the World Health Organization formulation. In this 
system, soft tissue tumours, including non-neoplastic tumour-like lesions, are 
categorized into three broad groups: 
1. tumours which differentiate along cell or tissue lines that have normal 
counterparts, i.e., fibrous tissue, fat, vessels, smooth muscle, nerve, ganglia, 
synovium, bone and cartilage; 
2. tumours whose lines of differentiation have no normal counterpart but which 
are consistent and recognized by a distinctive morphology, i.e, myxoma, 
epithelioid sarcoma, and alveolar soft part sarcoma; and 
3. tumours which are so poorly differentiated and morphologically unique that 
they defy classification. 
The vase majority of tumours fall into the first two groups. Overall, there are 
approximately 200 different entities, of which 80 are malignant. 
GRADING 
 
 
The histological typing of soft tissue tumours does not per se provide sufficient 
information on which to base therapeutic decision. Tumour grading is based on the 
concept that morphology reflects biological behaviour. The specific microscopic 
characteristic of soft tissue tumours that best predict their aggressiveness, i.e the 
potential for regional and distant metastasis, can be identified, integrated and 
represented by grade. 
The 1997 American joint Committee on Cancer (AJCC) and International Union 
Against Cancer (UICC) staging system for sarcoma of soft tissue (Fleming et 
al.,1997) is based upon a four-step grading, i.e, low, intermediate, high-grade and 
undifferentiated neoplasms. In this grading system, grade 1 and 2 tumours are 
considered low grade lesions with minimal metastatic potential; grade 3-4 neoplasms 
are high grade tumours that carry a significant risk of metastasis. Many institution 
continue to employ a three-step grading scale consisting of low (G1), intermediate 
(G2) and high (G3) grades. In this grading scale G1 lesions are considered to have 
minimal metastatic potential and are analogous to the G1 and G2 designations on the 
four-step scale for staging purposes. The G2 and G3 tumours on the three-step scale 
are analogous to  G3 and G4 on the four-step scale. The designation of grade is based 
upon a consideration and integration of each of these morphological features: degree 
of cellular differentiation, extent of necrosis, number of mitoses, cellularity, 
pleomorphism or anaplasia, quantity of matrix, vascularity, hemorrhage, vascular 
invasion and encapsulation . Among these variables, necrosis, mitoses and degree of 
differentiation appear to be the best predictors of outcome. Despite some lack of 
agreement on the number of grades employed and the significance of individual 
 
 
morphological parameters (there is inevitably a subjective component in assigning 
grade and only a part of the tumour is examined) grading, more than any clinical and 
pathological parameter available, is the most important prognosticator. 
 
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry has become increasingly important in diagnosing sarcomas 
(Ushigome et al.,1992). This technique is based on the utilization of visually tagged 
monoclonal or polyclonal antibodies directed against proteins found in specific cell 
types. Immunohistochemisty in soft tissue sarcoma : 
 
ANITBODY DISTRIBUTION 
Vimentin Almost all sarcomas and some carcinomas 
Keratin Almost all carcinomas and some sarcomas (Epithelioid 
sarcoma, synovial sarcoma) 
Desmin Leiomyosarcoma, rhabdomyosarcoma and occasionally 
MFH 
Neurofilmanet Primitive neuroectodermal tumour, neuroblastoma 
S-100 protein Malignant schwannoma, melanoma, clear cell (melanoma of 
soft parts), chondrosarcoma, leiomyosarcoma, 
rhabdomyosarcoma, liposarcoma 
Myoglobin Rhabdomyosarcoma 
 
 
Factor VIII-related 
antigen 
Angiosarcoma, Kaposi’s sarcoma 
Actin Leiomyosarcoma, rhabdomyosarcoma (MFH) 
EMA  Carcinomas, synovial sarcoma, meningioma 
Leu 7  Malignant schwannoma, leiomyosarcoma, synovial sarcoma, 
rhabdomyosarcoma 
 
 
STAGING 
The Task Force on Soft Tissue Sarcomas of the American Joint Committee on Cancer 
(AJCC) Staging and End Result Reporting and the Union Internationale Centre le 
Cancer (UICC) have established a staging system for soft tissue sarcomas which is an 
extension of the TNM system to include G for histological grade. Grade, size, depth 
and presence of nodal or distant metastases are the determinants of stage. This staging 
system is applied to all sarcomas of soft tissue except rhabdomyosarcoma (for which 
there is a special staging system), Kaposi’s sarcoma, dermatofibrosarcoma, desmoid, 
and sarcoma arising from the dura mater, brain, parenchymous organs or hollow 
viscera. The staging system was revised in 1997 with the addition of subgroupings of 
the T stage to designate superficial and deep lesion and the assignment of patients 
with nodal involvement to stage IV. Superficial lesions do not involve the superficial 
fascia in extremity lesions. For practical purposes, all retroperitoneal and visceral 
lesions would be deep lesions.  The staging system which places primary emphasis on 
extension beyond compartment is useful for planning surgical approach (Enneking et 
 
 
al.,1980). Compartmental status in combined modality treatment does not affect 
outcome to an important degree. 
 
 
 
 
 
AJCC staging system for sarcoma of soft tissues (AJCC Staging Manual, 1997):  
Histological Grade of Malignancy: 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated 
T Primary Tumour: 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour 5cm or less in greatest dimension 
T1a: superficial tumour 
T2b: deep tumour 
T2 Tumour greater than 5cm in greatest dimension 
T2a: superficial tumour 
T2b: deep tumour 
N Regional Lymph nodes: 
 
 
NX Region lymph nodes cannot be assessed 
N0 No histologically verified metastases to regional lymph nodes 
N1 Histologically verified regional lymph node metastasis 
M Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
Stage I 
A Low-grade, small, superficial and deep: G1-2 T1a-1b N0 M0 
B Low-grade, large, superficial: G1-2 T2a N0 M0 
Stage II 
A Low-grade, large, deep; G1-2 T2b N0 M0 
B High-grade, small, superficial and deep; G3-4 T1a-1b N0 M0 
C High-grade, large, superficial; G3-4 T2a N0 M0 
Stage III High-grade, large, deep; G3-4 T2b N0 M0 
Stage IV Any metastasis; any G any T N0 M0; any G any T N0 M1 
  
CLINICAL ASPECTS OF SPECIFIC SOFT TISSUE SARCOMAS 
1. Alveolar soft parts of specific soft tissue sarcomas. 
a. Tissue of origin (incidence), Unknown (rare) 
b. Features. Unique histology with no benign counterpart; often indolent 
even with lung metastases, which are common. The sarcoma most 
associated with brain metastases. Commonly affects the thigh in adults 
and the head and neck in children. The 5-year survival rate exceeds 
60%. 
 
 
2. Angiosarcoma (hemangiosarcoma, lymphangiosarcoma) 
a. Tissue of origin (incidence). Blood or lymph vessels (2%  - 3%) 
b. Feature of hemangiosarcoma. Affects the elderly; aggressive. Arises in 
many organs, notably the head and neck region, breast, and liver; 
especially affects the skin and superficial soft tissues (whereas most 
STSs are deep). Dedifferentiation from a hemangioma is rare. The 5- 
year survival rate is less than 20% 
c. Features of lymphangiosarcoma. Affects older adults; aggressive. 
Arises in areas with chronic lymphatic stasis (especially 
postmastectomy). The 5 – year survival rate is 10%. 
 
3. Clear cell sarcoma 
a. Tissue of origin (incidence). Now recognized as a form of malignant 
melanoma (rare). 
b. Features. Affects adults younger than 40 years of age; painless, firm, 
spherical masses on tendon sheaths and aponeurotic structures of distal 
extremities. The 5 – year survival rate is about 50 percent. 
4. Epithelioid sarcoma 
a. Tissue of origin (incidence), Unknown (rare) 
b. Features. Affects young adults; aggressive; typically appears on distal 
extremities. Epithelioid sarcoma and synovial sarcoma are the most 
common tumours of the hand and foot. Differs from other STSs by 
 
 
having a greater tendency to spread to non contiguous area of skin, 
subcutaneous tissue, fat, draining lymph nodes, and bone. The 5- year 
survival rate is 30%. 
5. Fibrosarcoma 
a. Tissue of origin (incidence), Fibrous tissue (5% to 20%) 
b. Features. Affects all age groups; arises in many mesenchymal sites; 
usually involves the abdominal wall or extremities. Ninety percent are 
well-differentiated (desmoid). Dermatofibrosarcoma protuberans (rare) 
develops on the skin of the trunk and almost never metastasizes. 
Fibromyxosarcoma affects any soft tissue site but usually develops on 
the extremities. Ten percent are poorly differentiated (high grade). 
Survival is directly related to tumour grade 
6. Malignant fibrous histiocytoma (MFH) 
a. Tissue of origin (incidence), Unknown (10% - 23%) 
b. Features. Age older than 40 years (less than 5% of affected patients are 
younger than 20 years of age). MFH has become a popular histolgical 
diagnosis, often encompassing tumours that were previously classified 
as pleomorphic rhabdomyosarcoma or undifferentiated fibrosarcom; it 
is the most common STS in some series. MFHs range from benign to 
atypical to frankly malignant. Develops in extremities (especially 
legs), trunk, and retroperitoneum. Superficial MFH develops close to 
the skin surface and is often low grade; the 5 – year survival rate is 
 
 
65%. Deep MFH usually is high grade; the 5- year survival rate is 30% 
to 80%. 
7. Hemangiopericytoma/solitary fibrous tumour 
a. Tissue of origin (incidence), Blood vessels or fibrous tissue (less 
than%). 
b. Features. Affects all ages. Develops under finger tips (glomus 
tumours), on lower extremities or pelvis, in the retroperitoneum, and 
elsewhere. Benign and malignant versions. The 5 – year survival rate 
is about 50%. 
      10.   Liposarcoma 
c. Tissue of origin (incidence), Fat tissue (15% - 18%) 
d. Features. Affects middle and older age groups, mostly men. Develops 
in thigh, groin, buttocks, shoulder girdle, and retroperitoneum. Does 
not arise from benign lipomas. The 5 – year survival rate is 80% for 
low grade liposarcomas and 20 % for high-grade liposarcomas. 
11.   Mesothelioma 
a. Tissue of origin (incidence). mesothelium 
b. Features. Age older than 50 years. Asbestos exposure is etiologic. 
Involves pleura and peritoneum; aggressively encases viscera. Highly 
lethal; the 5 – year survival rate is less than 10%. 
12.   Myxoma 
a. Tissue of origin (incidence).  Mesenchymal tissues 
 
 
b. Features. Usually found on extremities; has histological appearance of 
umbilical cord. The 5 – year survival rate is about 80%. 
13. Neurofibrosarcoma (schwannoma, neurilemoma) 
a. Tissue of origin (incidence). Nerve(5% - 7%). 
b. Features. Affects young and middle-aged adults and patients with 
neurofibromatosis type 1 (von Recklinghausen’s disease; about 10% 
develop sarcomatous changes during lifetime). Histologically 
resembles fibrosarcoma. Presents with thickening of nerves and 
without anatomic predilection. Superficial variety is low grade, 
spreads extensively along nerve sheaths without metastasizing, and has 
a  5–year survival rate of more than 90%. Penetrating variety is high 
grade with nodular growth, vascular invasion, and lung metastases and 
has 5-year survival rate of less than 20% 
. 
14. Rhabdomyosarcoma 
a. Tissue of origin (incidence). Straited muscle (5%-19%). 
b. Features. By definition in the G-TNM staging system, all are grade3. 
All types can occur in any age group. 
c. Features of embryonal rhabdomyosarcoma. Affects infants and 
children; sites are head and neck (70%) and genitalia (15%-20%). 
Includes sarcoma botryoid. The 5-year survival rate is about 70%. 
 
 
d. Features of alveolar rhabdomyosarcoma. Affects teenagers at any site; 
highly aggressive; histology resembles lung alveoli. The 5-year 
survival rate is about 50%. 
e. Features of pleomorphic rhabdomyosarcoma. Affects patients older 
than 30 years of age, is rare, and develops in extremities. Often is 
highly anaplastic; microscopically confused with MFH. The 5-year 
survival rate is about 25% 
15. Synovial sarcoma 
a. Tissue of origin (incidence). Tenosynovial mesothelium(5%-20%) 
b. Features. Affects young adults, but may occur from the second to 
fourth decade. Monophasic and biphasic subtypes are distinguished. 
Presents with hard masses, often painful, near tendons in the vicinity 
of joints of the hands, knees, or feet. Synovial and epithelioid sarcoma 
are the most common tumours of the hand and foot, often calcified, 
with characteristic radiographic appearance. The majority of synovial 
sarcomas are high grade. Lymph node involvement may be seen in up 
to 20% of cases. The 5-year survival rate is from 30%-50%. 
CLINICAL EVALUATION 
CLINCAL HISTORY 
The most frequent initial complaint is that of painless lump of a few weeks to several 
months duration. Occasionally, pain or tenderness precedes the detection of a lump. 
With progressive growth of tumour, symptoms appear which are secondary to 
 
 
infiltration of or pressure on adjacent structures (e.g, tendons, muscles, nerves) or 
organs. Occasionally symptoms secondary to the metabolic effects of the tumour 
products are seen, e.g, fever, anaemia, lethargy, weight loss, histamine-like reactions. 
These are not rare in patients with malignant fibrous histiocytoma (Enzinger and 
Weiss, 2001). To get clinical genetic data in sarcoma patients, the history should 
include details of the cause of death and history of malignant disease in siblings, 
parents, grandparents and progeny. 
ANATOMICAL SITE, SEX AND AGE 
Sites of appearance of soft tissue sarcoma in order of frequency are; lower extremity, 
upper extremity, torso, head/neck, retroperitoneum. There is only a very slight 
preponderance of soft tissue sarcoma in males. They are more common in older 
people, with 40 percent in persons > 55 years of age and 15 percent in patients < 15 
years of age (Enzinger and Weiss, 2001), Rhabdomyosarcomas almost always arise in 
children, synovial sarcomas develop in late adolescence and young adulthood and 
liposarcoma and malignant fibrous histiocytoma usually occur during mid and late 
adulthood. 
PHYSICAL EXAMINATION 
There must be a complete physical examination with particular attention paid to the 
region of the primary lesion : definition of size, site of origin (superficial or deep, 
attached to or fixed to deep structures), solitary or multinodular, involvement or 
discoloration of overlying skin, functional status of vessels and nerves, presence of 
 
 
distal oedema, muscular strength, range of motion of affected part, etc. If the patient 
has had prior excision, the operated site should be examined for presence of 
ecchymosis, status of wound healing, palpable evidence of residual tumour and 
location of drain site. The regional and  distant lymph-node groups need to be 
examined with care in all patients, especially those with large grade 2 and 3 (on a 
three step grading scale) sarcomas. Involvement of regional nodes is relatively 
frequent in patients with rhabdomyosarcoma and epithelial sarcoma, but uncommon  
in patients with fibrosarcoma and malignant fibrous histiocytoma. Myxoid 
liposarcoma not uncommonly metastasizes first to soft tissue or bone. 
NATURAL HISTORY 
LOCAL RECURRENCE 
One of the major clinical problems when treating soft tissue sarcomas is the 
propensity of the primary tumour to recur locally. Soft tissue sarcomas enlarge in a 
centrifugal fashion and compress normal tissue, giving the appearance of 
encapsulation. This pseudocapsule is actually composed of an inner compressed rim 
of normal tissue (compression zone) and an outer rim of edema and small newly 
formed vessels (reactive zone). Fingers of tumour can extend into and through this 
pseudocapsule provides surgeons with a tempting plane for dissection and invites a 
shell out procedure, such an excision leaves microscopic and often gross tumour in 
the wound. Excision of any sarcoma in the pseudocapsule is inadequate therapy and 
results in the development of local recurrences in up to 90% of patients. 
 
 
The site of a soft tissue sarcoma can certainly influence the technical ease with which 
resectability can be accomplished, hence it affects the potential for local control. For 
instance; lesions of the head and neck regions, where abutment to vital structures is 
often the case, are less likely to be controlled than lesion in the extremities. In the 
extremity, the site of the tumour may also have prognostic implications. Local control 
may be more difficult to achieve for proximal tumours than those more distally 
located, possibly because they achieve a larger size before detection. Simon and  
Enneking reported local recurrences following surgery alone in the buttock, groin, 
thigh, and areas below the knee to be 38%, 14%,15% and 0%, respectively. Potter et 
al, reported that among 115 patients with thigh sarcomas disease-free and overall 
survival was significantly worse for patients with tumour spread into the upper half of 
the thigh than for those with involvement limited to the distal thigh. In contrast, Yang 
et al found that patients undergoing multimodality treatment for sarcomas in the 
popliteal, axillary , or antecubital fossa had local control and overall survival rates 
similar to those for patients with purely intracompartmental extremity tumours. 
Hence the significance of location in the extremity may be less with multimodality 
therapy than with surgery alone. 
The time to local recurrence following surgery follows a predictable pattern. In one 
series of patients treated with surgery alone, approximately 80% of all lesions that 
were destined to recur locally did so within 2 years. 
Isolated local recurrences of soft tissue sarcomas, regardless of site, should be 
considered for further resection. A thorough evaluation for the presence of 
 
 
disseminated disease should be performed before contemplating resection of a local 
recurrence. 
DISTANT METASTASIS 
 Despite adequate local control of the primary lesion, many patients with high grade 
and a few patients with low grade soft tissue sarcomas succumb to metastatic disease.  
Although most patients with soft tissue sarcomas present without obvious metastases, 
many harbor occult micrometastasis that eventually become clinically evident. These 
patient represent a population who could benefit from adjuvant systemic 
chemotherapy along with removal of the primary tumour. 
As with local recurrence, the incidence and pattern of distant metastasis depends on 
the site of the primary sarcoma. Patients with retroperitoneal sarcomas had a greater 
tendency for local recurrence and disseminated disease throughout the abdomen. 
Patients with head and neck and truncal sarcomas had a higher local recurrence rate 
than those with extremity sarcomas. Treatment options for patients with metastatic 
disease include surgical resection if the tumour is localized to one organ system or 
systemic cytotoxic chemotherapy if it is not.  
 
LABORATORY INVESTIGATIONS 
Laboratory studies need not go  beyond a complete blood count and urinalysis for all 
but the exceptional patient. For patients with lesions in the abdomino-pelvic cavity, 
 
 
liver function and/or liver scan should be obtained as involvement of liver is not rare 
in such patients. 
IMAGING MODALITIES EMPLOYED TO EVALUATE SOFT 
TISSUE TUMOURS 
CONVENTIONAL RADIOGRAPHIC STUDIES 
The plain film radiograph obtained with low kilovoltage technique (below 50kvp) 
enhances the difference in radiographic density between fat and muscle and 
accentuated the soft tissue detail. Routine or over penetrated radiographs best 
demonstrate involvement of adjacent bone. Plain tomography is of particular value 
for assessing calcifications in soft tissue masses and for delineating soft tissue 
abnormalities adjacent to complex bony structures (pelvis, spine, chest wall, 
shoulder). Plain tomography augments but does not replace the plain radiograph The 
plain film is still invaluable for predicting the presence and nature of bony 
involvement.  When adjacent bone is involved by a slowly growing soft tissue mass, 
local pressure by the mass results in a scalloped pattern with a well define sclerotic 
margin which is most frequently encountered in benign process. Irregular cortical 
destruction is usually associated with fast-growing, frequently malignant lesions. 
Obliteration or displacement of normal fascial planes due to soft tissue infiltration is 
common in both benign and malignant tumours. Occasionally this interface is 
lobulated and smooth, suggesting the presence of a confining capsule. Few soft tissue 
tumours have a true capsule, and what resembles a capsule is imply a compressed rim 
 
 
of normal structures. Thus a smooth margin can be deceptive if it is automatically 
equated with benignancy. 
SONOGRAPHIC STUDIES 
Sonography provides an accurate method for detecting and determining the size of the 
soft tissue mass in the extremities due to differential patterns of echoes detected in the 
mass compared to those in normal muscle and fascia. This modality is far less reliable 
than CT or MR when the mass occurs in complex anatomic locations such as the 
pelvis, is located in deep soft tissues adjacent to bone, or occurs in the thorax 
surrounded by the lung. When the soft tissue mass occurs in other locations, 
particularly in the abdomen or extremities, sonography precisely establishes anatomic 
relations and tumour margins but generally provides considerably lesser anatomic 
detail than in available CT or MR.  Most soft tissue tumours have an echogenicity 
distinct from the adjacent soft tissues, which provides an interface between the 
tumour and surrounding soft tissues. The size and configuration of the mass can be 
accurately determined by sonography because the lesion can be visualized in both the 
transverse (axial) and longitudinal (sagittal) planes. Therefore sonography may be 
useful for following the size of the soft tissue mass on serial studies or the response of 
the lesion to treatment by non surgical means such as chemotherapy or radiation 
therapy. The echo pattern of solid masses is nonspecific, but a fluid-filled mass such 
as a synovial cyst (popliteal cyst) can be easily differentiated from a solid mass by 
sonography. Perhaps the best utility for sonography is an ultrasound-guided biopsy of 
a relatively superficial soft tissue mass. 
 
 
ANGIOGRAPHIC STUDIES 
Angiography is most helpful for evaluating the vascular supply of a soft tissue mass 
and the impact of the mass on adjacent structures. The angiogram typically performed 
with the digital subtraction technique (digital subtraction angiography, or DSA), 
provides information about the anatomic extent of the tumour, including its effect on 
adjacent structures, the arterial supply and venous drainage. Because these features 
influence the choice of operative procedures, angiography is a valuable adjunct to 
patient management. Much of this anatomic information can also be obtained in a 
noninvasive fashion via magnetic resonance angiography (MRA). Because the patient 
with a soft tissue tumour is likely to undergo MR scanning anyway, the referring 
physician should discuss with the radiologist the appropriateness of performing MRA 
as a supplement to the routine MR pulse sequences. Interventional angiographic 
procedures are sometimes necessary, occasionally to embolize  a highly 
hypervasuclar soft tissue mass preoperatively or, rarely, to embolize a persistent 
arterial bleeder following surgical resection of the lesion. 
Malignant soft tissue tumours have angiographic patterns that range from 
hypervascular to hypovascular. The angiographic features of neovascularity, 
puddling, and tumour blush are typical of malignant tumours, although benign 
tumours also occasionally demonstrate neovascularity. Malignant soft tissue tumours 
are frequently heterogeneous and contain less-vascular areas, corresponding to areas 
of hemorrhage and necrosis along with  hypervascular areas that correspond to viable 
 
 
tumour. Unsuspected satellite tumours adjacent to a primary mass may also be 
discovered by angiography. 
Certain angiographic patterns are suggestive of specific histologic diagnoses such as 
hemangiomas and vascular malformations. Hemangiopericytoma is another tumour 
that may exhibit a unique and striking hypervascular pattern. A frequent angiographic 
feature of hemangiopericytoma is that early during the arterial phase the main arteries 
are displaced around the periphery of the tumour. Later, the feeding arteries spread in 
a meshwork pattern before penetrating the lesion. This peripheral vascular 
distribution noted at angiography correlates well with the plexiform meshwork of 
vessels covering the tumour seen on inspection of the gross specimen. This 
angiographic pattern is highly suggestive of hemangiopericytoma. In most soft tissue 
masses, however, a specific pathologic diagnosis cannot be predicted reliably by 
angiography. 
CT SCANNING 
Computed tomography has proved helpful for detecting soft tissue tumours and 
monitoring the patient for local recurrence and distant metastates. Therefore if a 
patient is to undergo CT scanning or MR imaging, it is imperative that it be done 
prior to any biopsy or surgical intervention. If this principle is ignored, the value of 
the combined imaging studies is dramatically diminished because it becomes 
difficult, or even impossible to assess how much of the soft tissue abnormality is due 
to the lesion versus surgically induced changes such as edema and hemorrhage. CT 
scanning is most useful for defining the extent of the soft tissue mass and its relation 
 
 
to adjacent structures, especially in complex anatomic sites such as the pelvis. This 
exquisite anatomic detail enables the surgeon to perform more complete resection of 
the tumour and the radiotherapist to define a more precise radiation therapy field. 
Occasionally, CT scanning can help establish a diagnosis, especially with regard to 
detection of adipose tissue in tumours whose fatty component may not be appreciated 
on plain radiographs. Contrast enhancement is valuable for assessing the vascularity 
of the soft tissue mass and distinguishing the mass from adjacent structures, 
especially the vascular bundle. Soft tissue tumours can also be isodense with normal 
muscle on precontrast CT scans and become evident only following contrast infusion. 
CT scanning is superior to MR imaging for detecting and characterizing calcification 
in the soft tissue mass and detecting subtle cortical erosion and periosteal reaction in 
the bone adjacent to the mass. The ability of CT scanning to detect calcification in the 
soft tissue mass can prove invaluable for suggesting  a specific diagnosis. For 
example, phleboliths suggest hemangiomas; calcified rings and arcs suggest a 
cartilaginous lesion; amorphous calcification in a large soft tissue mass suggests a 
soft tissue osterosarcoma or synovial sarcoma; and peripheral calcification 
surrounding a soft tissue mass suggests myositis ossificans, whereas calcification 
throughout the lesion favours tumoral calcinosis. 
MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging is arguably the most important technologic innovation in 
medicine during the last 15 years. Both the CT and MR are expensive and depend on 
sophisticated computers that rapidly analyze millions of complex differential 
 
 
equations. There are significant differences between the two methods. A major 
advantage of MR imaging is its ability to image the region of anatomic interest 
directly in orthogonal planes (i.e., axial, coronal, and sagittal planes). This capability 
and the excellent soft tissue contrast of the image are invaluable when assessing the 
extent of a soft tissue mass. 
Most soft tissue tumours exhibit a low signal intensity (i.e., they appear dark) or 
intermediate signal intensity on T1-weighted scans; and they exhibit a high signal 
intensity (i.e., they are bright or white) on T2 weighted scans. Therefore MR provides 
little diagnostic specificity for most soft tissue tumours, as explained earlier in the 
chapter. However, one group of tumours typically have a high signal on T1-weighted 
scans, including hematomas, lipomas, liposarcomas, hemangiomas, and lesions 
complicated by hemorrhage into a preexisting tumour. The histologic picture of these 
lesions varies, but all contain blood or fat. In contrast, flowing blood, unlike the 
stagnant blood in a hematoma, has a low signal intensity, permitting assessment of 
vessel patency. Lesions that are predominantly fibrous exhibit low signal intensity on 
both  T1- and T2-weighted images.  
Most soft tissue masses have a nonspecific appearance on MR imaging; but even so, 
this technique is the imaging modality of choice for determining (in three orthogonal 
planes) the extent of the lesion. If the plain radiograph obtained from the patient with 
a palpable soft tissue mass fails to demonstrate bony involvement or calcification in 
the soft tissue lesion, only MR imaging ( not CT scanning ) need be performed. 
BIOPSY  
 
 
Properly performed, a timely biopsy is the critical first step in multimodality 
treatment approach. Improperly done, it can complicate patient care and sometimes 
even eliminate treatment options. Several biopsy techniques are available to the 
clinician: fine needle aspiration, core-needle biopsy, incisional biopsy, and excisional 
biopsy. The choice of biopsy is dictated by the size and location of the mass and the 
experience of the pathologist. Excisional biopsy should be reserved for small (<3-5cm 
in greatest diameter) and superficial soft tissue masses where the chance of 
malignancy is low and where complete excision would not jeopardize subsequent 
treatment in the event a sarcoma is found. 
Fine-needle aspiration (FNA) involves use of a fine-gauge needle (usually 21-23 
gauge) to aspirate individual tumour cells from a mass. FNA cytology has a role to 
play in the diagnosis of some soft tissue lesions, but its use should be limited because 
even experienced cytopathologists are often unable to discern the grade and histologic 
type of  a sarcoma from the small cellular sample of an aspirate. The advantage of 
FNA is that it is relatively atraumatic and hence can be used to sample deep-seated 
tumours (e.g., retroperitoneal masses) under computed tomography (CT) guidance. 
FNA minimizes the potential for tumour spillage in the peritoneal cavity that can 
accompany open surgical biopsy of a retroperitoneal sarcoma. CT-guided FNA has 
proven helpful for diagnosing intraabdominal and retroperitoneal tumours but is 
rarely needed for extremity sarcomas. FNA biopsy is also acceptable for documenting 
local or distant recurrence in patients with a previously diagnosed sarcoma, where the 
cytology findings can be directly compared with the  prior histology specimens. 
 
 
Core-needle biopsy results in the retrieval of a thin sliver of tissue (app. 1×10m). 
Here again, the small sample size may make it difficult for a pathologist to diagnose 
the tumour accurately, or the tissue obtained may not be representative of the entire 
tumour, leading to an underestimate of the grade. Tissue necessary for special stains 
or electron microscopy may not be available with this technique. Previously 
expressed fears that core-needle biopsy of extremity sarcomas would result in a 
significant number of hematomas – and hence the dissemination of tumour cells 
beyond the confines of the primary lesion – appear groundless. Several series have 
compared core-needle and open biopsies of soft tissue tumours and documented that 
both the histologic type and grade of a sarcoma could be correctly determined by 
core-needle biopsy in about 90% of cases. Moreover, the core-needle biopsy 
approach is more cost-effective. These results have encouraged wider use of this 
technique, including core-needle biopsies using CT guidance. 
Excisional biopsy refers to removal of the entire grossly evident lesion, usually 
without a significant margin of normal tissue. Many sarcomas appear to be 
encapsulated at the time of open biopsy. In actuality, these tumours have a 
“pseudocapsule”, and removing the tumour through its pseudocapsule leaves gross or 
microscopic cancer behind in many cases. “Shell out,” or excisional biopsy, should be 
reserved for lesions less than 3-5cm in diameter or for extremely superficial tumours. 
Excisional biopsies of large or deep sarcomas are undesirable as they can contaminate 
surrounding tissue planes, which may compromise the subsequent definitive surgical 
procedure. 
 
 
Incisional biopsy involved removal of a generous wedge of tissue that is minimally 
manipulated at the time of surgery. There are several important technical factors 
when  performing an incisional biopsy. For extremity lesions, the incision is oriented 
along the long axis of the extremity. For truncal or retroperitoneal lesions, the biopsy 
incision is situated so it can be readily excised along with the tumour if a sarcoma is 
diagnosed. The biopsy site should be directly over the tumour, at the point where the 
lesion is closest to the surface, and there should be no raising of flaps or disturbance 
of tissue planes superficial to the tumour. Prior to wound closure, careful attention is 
paid to hemostasis to minimize the likelihood of a  hematoma, which could 
disseminate tumour cells through normal tissue planes. Drains are not used routinely; 
in the uncommon case where a drain is required, it should exit either though or near 
the biopsy incision. If malignancy is diagnosed, the drain tract must be excised in 
continuity with the tumour mass. 
A frozen section examination  at the time of biopsy can be useful for determining 
whether the specimen contains viable lesional tissue for examination, in contrast to 
nonviable tumour or nonlesional reactive tissue surround the tumour. Because of the 
subtle criteria necessary to distinguish benign from malignant soft tissue tumours and 
the importance of proper grade assignment, treatment planning (including definitive 
resection) is almost always deferred until a definitive report based on permanent 
sections is available. 
TREATMENT OF LOCALIZED TUMOURS 
SURGICAL THERAPY 
 
 
Surgery is the mainstay of any treatment approach for a clinically localized primary 
or recurrent soft tissue sarcoma. As has been described, however, removal of the 
gross tumour mass from within its pseudocapsule is associated with a prohibitively 
high likelihood of local recurrence. With the appreciation of the infiltrative nature of 
these tumours, radical procedures such as amputation came to be accepted as the 
standard for surgical therapy. Enneking classified surgical procedures for extremity 
sarcomas according to the margins achieved. He described four types of excision. 
1. Intracapsular excisions are performed inside the pseudocapsule and are often 
piecemeal in nature. An amputation that passes within the pseudocapsule is 
called an intracapuslar amputation. The likelihood of local recurrence with 
intracapsular procedures is virtually 100%. 
2. Marginal excisions are en bloc resections performed through the tumour. 
Excisional biopsies and “shellout” procedures fall into this category. An 
amputation performed though this marginal zone is called a marginal 
amputation. Local recurrences are expected 60-80% of the time. 
3. Wide excisions are an en bloc resections done through normal tissue beyond 
the reactive zone but within the muscular compartment of origin, leaving 
place some portion of that compartment. The pseudocapsule is removed en 
bloc, and the tumour is never visualized during the procedure. The reported 
local recurrence rate following wide excision alone varies depending on 
selection criteria and the adequacy of the margin as assesed histologically, but 
overall it is approximately 30%. An amputation can be considered a wide 
 
 
amputation if it is performed though normal tissue proximal to the reactive 
zone but remains within the compartment of involvement. 
4. Radical excisions are en bloc resections of the tumour and the entire 
compartment of origin, leaving no remanents of the compartment intact. A 
radical amputation usually requires disarticulation of the joint proximal to the 
involved compartment and results in removal of the entire compartment at 
risk.  
COMPARTMENT EXCISIONS 
For tumours that arise entirely within an anatomically defined muscular compartment, 
excision of the muscles comprising that compartment from origin to insertion is often 
successful in achieving local control. The thigh, which is the site of more than 50% of 
all extremity sarcomas, has three major compartments bound by the fascial at and its 
extension. The anterior compartment includes primarily the quadriceps and sartorius 
muscles, which can be removed along with the femoral nerve. An anterior 
compartment excision results in knee weakness and instability, which can be 
improved with the use of the transplanted gracilis and short head of the biceps. Even 
without such reconstruction, patients can ambulate after an anterior compartment 
excision by using the hip flexor to throw the leg forward; gait is improved with the 
use of a locking knee brace. The medial thigh compartment consists of the gracilis, 
adductors (minimus, brevis, longus, and magnus), and pectineus muscles. Medial 
compartment excision is generally well tolerated with only limited functional deficit. 
 
 
Posterior compartment excision removes the hamstring muscles (semimembranous 
and semitendinosus and biceps femores), as well as the posterior portion of the 
adductor magnus muscle. Ambulation is surprisingly well maintained after this 
surgery, with knee flexion brought about by the action of the gracilis and soleus 
muscles on the distal femur. Buttockectomy entails removal of the entire gluteus 
maximus muscle for tumours localized entirely within this muscle. 
LIMB-SPARING PROCEDURES                 
Rosenberg et al, compared radical amputation to wide local excision plays 
postoperative irradiation in a prospective, randomized trial. Patients who underwent 
limb-sparing surgery had a survival rate identical to those undergoing amputation, 
despite a slightly higher local recurrence rate (19% Vs 6%, a difference that was not 
statistically significant). This study demonstrated the merit of lib-sparing approached 
to extremity sarcomas. Radical amputation is currently reserved for patients who are 
not suitable candidates for limb-sparing approaches, usually because of abutment to 
bone or major neurovascular structures or an extremely large tumour size. It is of note 
that the location of the tumour distally in the extremity (hand or foot) is not 
necessarily an indication for amputation. Local control with acceptable with limb-
sparing approaches in most of these cases. 
Most current limb-salvage protocols include wide excision as the definitive surgical 
procedure. Wide excision involves gross total removal of the tumour with a wide 
margin of normal tissue, but no attempt is made to resect an entire muscle 
compartment. Rather, a margin 3-5cm of normal tissue is obtained proximally and 
 
 
distally. It includes excision of some overlying skin to encompass all previous scars 
or biopsy sites. Tumour should not be visualized during the excision so tumour cells 
are not spilled into the surgical bed. On the lateral deep margins, at least one grossly 
uninvolved fascial plane is resected en bloc with the tumour for large or deep-seated 
tumours, resection of uninvolved periosteum or adventitia my represent the deep 
margin. Removal of periosteum should be limited to areas directly abutting tumour to 
minimize the likelihood of post irradiation pathologic fracture. If necessary, major 
vascular structures may be resected and reconstructed with graft material. On 
occasion, major nerves (e.g., sciatic nerve) are sacrificed to preserve a functional 
albeit neurologically compromised extremity. Because of their less aggressive nature, 
when low grade lesions are resected major vessels or nerves are not taken along with 
the tumour. Placement of titanium clips outlining the limits of the excision is essential 
as a guide to the radiation therapist for constructing the radiation treatment portal. 
Suction catheters are placed at the end of the dissection to allow evacuation of any 
blood and serous fluid from the operative bed and to promote the adherence of skin 
flaps. 
The use of multimodality therapy (particularly preoperatively) is associated with a 
high incidence of wound complications. These complications can be disastrous in an 
irradiated wound or if major vessels, nerves or bone become exposed. To minimize 
the likelihood of wound breakdown, consideration should always be given to 
reconstructing the surgical defect with free or pedicled myocutaneous flaps. Barwick 
et al, articulated the criteria for primary closure of a wide excision wound in patients 
undergoing multimodality therapy. The skin edges should be approximated without 
 
 
tension, and the resection site must not have exposed bone, nerve, blood vessel, or 
tendon present. If the skin edges cannot be approximately without tension but the 
base of the resection is entirely muscle, a split-thickness skin graft should be applied; 
otherwise, a flap reconstruction is performed. Irradiated wounds in the trunk and 
retroperitoneum may present a formidable technical challenge to the reconstructive 
surgeon. 
 
RADICAL AMPUTATIONS 
Below-knee amputation is performed through the tibia and fibula and allows a stump 
to be used for fitting a prosthetic device. Rehabilitation from this procedure is usually 
satisfactory. Below-knee amputation is the radical resection for any soft tissue 
sarcoma of the foot. Above-knee amputation can be performed at any level distal to 
the lesser trochanter to allow enough stump for a prosthesis. This amputation does not 
constitute a radical excision for tumours above the knee, as the entire compartment is 
not removed. Hip disarticulation entails complete removal of the femur at the hip 
joint. Most muscles attached to the lower extremity are removed in their entirety. This 
procedure constitutes one option for radical excision for patients with lesions of the 
middle and lower thigh. Hemipelvectomy involves removal of the entire lower 
extremity and hemipelvis removal of the entire lower extremity and hemipelvis, with 
disarticulation of the sacroiliac joint and pubic symphysis. This procedure is a radical 
amputation for patients with proximal thigh and buttock tumors. The standard 
hemipelvectomy utilizes a posterior flap of skin and subcutaneous tissue overlying 
 
 
the buttock. For buttock and posterior thigh lesions, it is possible to construct an 
anterior myocutaneous flap based on the quadriceps muscles and superficial femoral 
artery to cover the surgical defect. Modified hemipelvectomy preserves the iliac 
wing, which allows improved patient rehabilitation. It is similar to the standard 
hemipelvectomy except the sacroiliac joint is preserved and the iliac bone is divided 
below the level of the sciatic notch. Because this involves transaction of muscles in 
the buttock, it is not suitable for lesions in this area. Internal hemipelvectomy is not 
generally employed for soft tissue tumours; it involves removal of the hemipelvis 
without amputation of the extremity and can be useful for management of bony 
tumours of the hemipelvis. 
For tumours of the hand and wrist requiring radical amputation, below-elbow 
amputation is used. Above-elbow amputation is used for tumours of the forearm. 
Shoulder disarticulation is reserved for distal arm and elbow lesions. Forequarter 
amputation (interscapulothoracic amputation) is applied to the treatment of lesions of 
the axilla, shoulder girdle, or proximal arm. This procedure includes removal of the 
entire upper extremity along with the scapula and clavicle.  
The means required to achieve a radical excision depend in part on the anatomic 
location of the tumour and its size. Many tumours of the extremities are not located in 
distinct anatomic compartments, and hence a radical excision cannot be achieved 
except by amputation. Similarly, large tumours localized to one compartment but that 
abut bone or major neurovascular structures cannot be radically excised without 
amputation. A radical excision, as defined by Enneking, Is not required for all 
 
 
sarcomas. With the use of adjuvant radiation therapy, local control rates with less 
radical resections have improved and match those achievable with radical surgery. 
Currently, wide excision is the procedure of choice for low grade sarcomas or higher 
grade tumours that are to be treated with multimodality therapy. Marginal excision is 
frequently all that can be achieved for treatment of retroperitoneal and head and neck 
sarcomas; intracapsular excision is not generally performed except for the occasional 
low grade tumour for which any other type of excision would cause an unacceptable 
loss of function. Adjuvant irradiation should almost always be considered when 
tumours must be treated with marginal or intracapsular excisions. 
 Overall local control was obtained in approximately  80% of patients undergoing 
radical resection regardless of whether amputation was performed. Unfortunately, 
even a “radical” excision is not always associated with an adequate margin when the 
resected specimen is examined histologically. When histologic evaluation verified 
that adequate margins were obtained with the radical procedure, the local failure rate 
was 5%. If microscopic tumour was found at or within 1 mm of the surgical margin, 
the local failure rate rose to 89%. Inadequate margins were most commonly 
associated with large proximal thigh and groin tumours. More distal extremity 
tumours rarely had tumour at or close to the surgical margin after appropriate radical 
excision and the local control rate can be expected to approach 100% after radical 
amputation of distal extremity sarcomas. 
Although radical excisions that achieve a histologically negative margin are 
associated with high rates of local tumour control, the functional, psychological, and 
 
 
cosmetic costs can be high. For this reason, radical surgery as single modality therapy 
has gradually been replaced by more conservative resection performed as part of 
multidisciplinary, multimodality treatment approaches. Nowhere is this trend more 
evident than during treatment of extremity soft tissue sarcomas with multimodality, 
limb-sparing therapy. 
 
 
 
RADIATION THERAPY 
POSTOPERATIVE RADIATION THERAPY                                              
 Postoperative radiation therapy after wide excision provides excellent local control 
for primary extremity sarcomas up to 10 cm in size. The randomized trial of 
amputation versus wide local excision previously cited validated the concept of limb-
sparing surgery combined with postoperative irradiation. Generally, a total of 60 Gy 
or more is required to ensure local control. At these dose levels the entire 
circumference of the extremity must not be irradiated, in order to avoid massive 
lymphedema. In practice, a strip of skin and subcutaneous tissue away from the 
tumour is excluded from the treatment field to prevent this complication. 
 
 
Radiation can also be delivered to the tumour bed postoperatively by means of 
implanted radioactive sources, a technique referred to as brachytherapy. This 
approach has the advantage of a much shorter time to initiation and completion of 
therapy (usually begun within a week of operation and completed in 4-5 days, 
compared with 6-7 weeks of external beam radiation beginning a month or more 
postoperatively). On the other hand, brachytherapy is technically complex and 
requires the presence of an experienced radiation oncologist in the operating room. A 
randomized trial demonstrated a significant decrease in local recurrences for high 
grade sarcomas after combined surgery and postoperative brachytherapy compared 
with surgery alone. Patients with low grade sarcomas did not benefit from adjuvant 
brachytherapy, although a recent effectively decreased local recurrence of these 
tumours. Otherwise, brachytherapy and external beam radiation appear to be 
equivalent when properly administered. The date from these two randomized trials 
provide strong support for the routine inclusion of radiation therapy (by some 
technique) in all patients with high grade, and many if not most patients with low 
grade, extremity sarcomas undergoing limb-sparingly surgery. 
PREOPERATIVE RADIATION THERAPY 
Preoperative irradiation followed by conservative surgery offers several theoretic 
advantages. The treatment volume is restricted to the known or probable extension of 
tumour. This means that a smaller volume can be treated than is the case with 
postoperative irradiation, as the latter must cover all tissues manipulated or handled 
during the surgical procedure. The resection may be of a lesser magnitude if tumour 
 
 
regression is obtained with preoperative irradiation. Seeding the surgical bed with 
viable tumour cells may be reduced. Tumours initially considered unresectable 
without amputation, shrunk sufficiently to permit limb-sparing resection. 
Enneking and McAuliffe have reported their experience utilizing preoperative 
irradiation followed by wide or marginal resection of low and high grade extremity 
sarcomas. They compared their results with comparably staged, matched control who 
underwent either a limb-sparing procedure or amputation without preoperative 
irradiation. Local recurrence rates were highest in the group undergoing limb-sparing 
surgery alone (37%) and were significantly higher than in those undergoing 
preoperative irradiation plus surgery (3%). In the same series, patients undergoing 
limb-sparing procedures reported substantially better postoperative function than 
those with amputation. The use of preoperative treatment for large extremity 
sarcomas has increased the number of patients who can be considered for limb-
sparing surgery. 
ISOLATED LIMB PERFUSION 
Hyperthermic isolated limb perfusion with chemotherapeutic agents has been tried as 
another way to control very large tumours that would otherwise require amputation 
because of proximity to nerve or blood vessels. Most such regimens  do not appear 
superior to surgery plus radiotherapy. However, hypothermic TNF-α plus melphalan 
has achieved complete responses rates of approximately 30%,partial remission rates 
of 50 % with overall limb-salvage rates over 80% (Schraffordt Koops et al., 1998). 
 
 
This work was initiated by Lejeune et al, (1989) and has been extended to several 
other centers. TNF-α has long been known to be potent non-specific tumour cell 
cytotoxic agent with demonstrated high efficacy in treatment of tumour-bearing 
rodents. Application in man  has been severely restricted due to systemic toxicity. 
However, by the use of the isolated limb perfusion technique, the systemic toxicity 
has been effectively bypassed. Effermont et al (1996) reported the result from a multi-
centre study of isolated limb perfusion with TNF-α, interferon-γ (IFN γ)  and 
melphalan for extremity sarcomas. The complete response (CR) and partial response 
(PR) rates were 18% and 64%; limb salvage was achieved in 84% of patients. Of 39 
patients who also had conservative resection, there have been five local failures. 
Vaglini et al, (1994) reported from Milan a high response rate using the same 
protocol. 
ROLE OF ADJUVANT CHEMOTHERAPY 
Although surgery and radiotherapy achieve control of the primary tumour and cure 
most adult patients with soft tissue sarcomas, many patients, especially those with 
large grade 2 or 3 primaries, die of metastatic disease not evident at diagnosis. 
Several studies have shown chemotherapy to be effective against clinically evident 
metastases .This has suggested to many that chemotherapy used as an adjuvant 
therapy (in high-risk stage MO patients) would inactivate micrometastases and 
increase long-term survival. 
The first prospective randomized trial of adjuvant chemotherapy for this group of 
tumours was reported form the M.D.Anderson Hospital (Lindberg et al.,1977); they 
 
 
failed to demonstrate any advantage of vincristine, cyclophosphamide, Adriamycin 
and dactinomycin chemotherapy over untreated controls. Similarly, a randomized 
Mayo Clinic series (Edmonson et al., 1984) found a slight extension of disease-free 
survival with no increase in overall survival for patients receiving vincristine, 
cyclopohosphamide and dactinomycin alternating with vincristine, doxorubicin and 
dacarbazine (DTIC). 
However, using Adriamycin (530mg/m2) and cyclophosphamide (500-700 mg/m2   
Followed by high-dose methotrexate, Rosenberg et al, (1983) demonstrated a 
significantly improved disease-free survival for patients with extremity lesions 
randomized to adjuvant chemotherapy (92% Vs 60% at e years with a survival 
advantage of 95% Vs 74%). Some serious cardiotoxicity was encountered. With 
longer follow-up in this small randomized trial, the survival advantage was no longer 
significant (Chang et al., 1988). Single-agent doxorubicin has failed to show an 
improvement in disease-free or overall survival in patients receiving postoperative 
chemotherapy compared with surgery alone. 
A metastasis of 13 randomized trials of adjuvant chemotherapy versus control in soft 
tissue sarcomas demonstrated that Adriamycin-based chemotherapy yielded an 
absolute gain in overall recurrence-free survival of 10% from 45% to 55% (P= 
0.0001) and a trend for improvement of overall survival of 4% from 50-54% 
(P=0.12). For local control the gain was 6% at 10 years, viz. 75% -> 81%, P = 0.016. 
the most clear evidence of a gain in survival obtained for patients 31-60 years old, 
recurrent lesions, extremity and high grade (Sarcoma Meta-analysis Collaboration, 
 
 
1997). Encouraging results with more intense adjuvant therapy was reported by 
investigators at Massachusetts General Hospital who evaluated doxorubicin, 
ifosfamide and DTIC chemotherapy and radiation in adult patients with  > 8cm AJCC 
(1992) stage IIB or IIIB soft tissue sarcomas of the extremity (Spiro et al., 1996; 
DeLaney et al., 201). Moreover, a newer randomized trial of more intense adjuvant 
chemotherapy with epirubicin, ifosfamide, mesna and granulocyte colony stimulating 
factor (G-CSF) also seems to show a possible further advantage in disease-free and 
overall survival (Frustaci et al., 2001). 
DISEASE (METASTATIC STAGE IVB) 
CHEMOTHERAPY 
Doxorubicin and ifosfamide have been demonstrated to be the most active 
chemotherapy agent in widely disseminated soft tissue sarcoma. For doxorubicin, 
objective response rates between 20% and 40% for the single agent have been 
reported. A steep dose-response curve for objective responses was described by 
O’Bryan et al, (1977)’ 0% at  45mg/m2 , 20% at 60mg/m2 and 37% at 75mg/m2. 
Complete responses were few, durations averaged 8 months with little survival 
advantage conferred by single-agent treatment. DTIC by itself has a modest response 
rate around 16% (Gottlieb et al., 1976). Methotrexate was described as active in 36% 
of 41 patients with six complete responders (Subramanian and Wiltshaw, 1978). 
High-dose methotrexate may be active as initial therapy but of limited value in pre-
treated patients (Karakousis et al., 1980). Cyclophosphamide appears less active in 
adults than in children and less active than the related compound ifosamide (Branwell 
 
 
et al., 1993). High dose of ifosfamide may be particularly active (Christmas et al., 
1993”),, Cisplatin may have a role (Karakousis et al., 1979; Grabois et al., 1994) 
Pinede and Verweij (1986) and Greenall et al,(1986) have reviewed numerous other 
agents evaluated in small trials. 
Many combination chemotherapy regimens for metastatic disease have been studied 
in phase II trials. Most of these trials include doxorubicin (or epirubicin) and an 
alkylating agent. Adding DTIC to doxorubicin improved the response rate to 41% as 
described by Gottlieh et al, (1972), but the response rate has decreased over time 
(Gottlieh et al, 1976). Randomized trials (Omura et al., 1983; Borden et al., 1987) 
found some gain f\or the combination. A South-West Oncology Group (SWOG) 
phase III trial compared bolus versus infusional administration of doxorubicin plus 
DTIC and reported no differences in overall response (17% in both arms) or complete 
responses (5% in both arms). Additionally, there was no difference in the median 
survival, 10.5 months in both groups (Zalupski et al., 1991). Adding 
cyclophosphamide to the basic duo was reported to raise the response rate to 56% 
(Blum et al., 1980) and this was confirmed  by a randomized trial (Baker, 1987). 
Comparisons have shown that the addition of less active drugs necessitate lower 
doses of doxorubicin and , accordingly, reduces overall effectiveness (Cruz et al., 
1979; Schoenfeld et al., 1982). Adding ifosfamide seems to be clearly beneficial as 
report by Blum et al, (1993) and Schutte et al, (1993). 
The ECOG conducted a three-arm trial comparing doxorubicin alone, doxorubicin 
plus ifosfamide, and mitomycin plus doxorubicin plus cisplatin. Objective tumour 
 
 
regression occurred more frequently in the combination arms than in the single-agent 
arm (20% with doxorubicin alone, 34% in doxorubicin plus ifosfamide, and 32% in 
the mitomycin plus doxorubicin plus cisplatin arm); However, the combination 
regimens resulted insignificantly greater myelosuppression. e.g, 80% of the 
doxorubicin/ifosfamide group had grade 3 or greater myelosuppression. Most  
notably, no significant survival differences were observed between the three 
treatment regimens (Edmonson et al., 1993). 
The extensively utilized CYVADIC regimen have evolved from the sequential trials 
sponsored by SWOG (Gottlieh et al., 1975). Greenall et al., (1986) reviewed studies 
reporting response rates of 15-60%, the average being 41%. Noteworthy is that up to 
15% of the responses have been scored as complete. The median response was longer 
(13 months) and 21% of complete responses described by Yap et al,(1986) have also 
reviewed alternative regimens. A popular regimen adds ifosfamide to Adriamycin and 
DTIC (Elias and Antman, 1986). A combination of ifosfamide with mesna, 
doxorubicin and DTIC has resulted in response rates in measurable metastatic 
sarcomas as high as 47% with complete response rates as high as 10% (Chang et al., 
1989; Elias et al., 1989). Another protocol described activity with DTIC and cisplatin 
in pretreated patients (Piver et al., 1986). 
Dose intensity may be extremely important as described by Zanineli et al., (1993). 
Very high-dose ifosfamide had been used by Rosen et al, (1994) with high response 
rates despite some toxicity. Higher-dose therapy with standard agents (Bodey, 1981) 
may require special supportive care such as bone marrow transplantation (Kesinger et 
 
 
al., 1994), but may offer a chance for higher complete response rates and longer 
response duration. There has been a considerable interest focused on maintaining 
dose intensity of chemotherapy using colony stimulating factors to alleviate 
myelosuppression. Granulocyte/macrophage colony stimulating factor (GM-CSF) has 
been used with a variety of regimens to help maintain dose intensification. In a few 
studies this has resulted in improved response rates (Mertens and Bramwell, 1993). 
Even higher dose chemotherapy, as used at M.D. Anderson, seems to result in higher 
response rates (59-69%) (Pisters et al., 1997; Patel et al., 1998). 
PULMONARY SURGERY FOR METASTATIC DISEASE 
Distant metastases usually present 2 years after the initial diagnosis. Patients with 
high-grade sarcomas have a higher risk of developing distant disease compared with 
low-grade extremity sarcomas (Donohue et al., 1988). For patients with extremity 
tumours, metastatic disease most frequently appears in the lungs (Gadd et al., 1993). 
Evidence is now available that resection of pulmonary metastases may be worthwhile 
in selected patients. Factors such as disease-free interval (time elapsing between 
resection of the primary tumour and appearance of pulmonary metastases) and 
tumour doubling time (calculated from measurements of the diameter of pulmonary 
nodules seen on serial chest X-rays) influence prognosis. The following criteria for 
selection of patients for surgery have been suggested (Joseph, 1974): 
• Control of the primary tumour has been achieved; 
• There is no evidence of extrapulmonary metastases; 
 
 
• Pulmonary lesions should be resectable, multiple lesions are not a 
contraindication but if extensive multiple resections are necessary the failure 
rate rises; 
• The patient should be fit for surgery as regards general condition and 
respiratory status; 
• Tumour doubling time should be atleast 40 days, 
Complete resection of pulmonary lesions is possible in some patients who have 
limited disease and adequate pulmonary function.  
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MATERIALS AND METHODS 
Though the soft tissue sarcomas rare tumours, In our institution,we are treating a 
significant number of soft tissue sarcomas, Since our hospital has well established 
oncology department. The study design is a retrospective analysis about “Limb 
salvage in extremity soft tissue sarcomas”. This Study was conducted in 
Government Royapettah  Hospital . Study period was  5 years duration between (Jan’ 
2001 – Dec’  2005). All the extremity soft tissue sarcomas patients who were 
attending our outpatient department and underwent treatment included in this study. 
All the age group of patients were taken for this study. Sex prevalence has been 
calculated. 
Any soft tissue swelling which were > 5cms, or any suspicion of malignant features 
like sudden increase in size , adherent with a underlying fascia, recurrence after 
excision and any evidence of metastasis, these patients were subjected to Trucut 
Biopsy after thorough clinical examination. 
For superficial swelling, that are smaller than 5cm, particularly those were suspected 
for malignancy, Excisional biopsy was done. For more than 5cm sized and deep 
seated either Trucut biopsy or Incisional biopsy were  done . Trucut biopsy was done 
in such way that the needle punctured site and track of the needle pathway were 
included in definitive surgery, If it could be proved to be as soft tissue sarcoma.  
Incisional biopsy - the incision was made along the long axis of the affected limb, 
within the tumour limit and was planned to include the biopsy scar in following 
 
 
definitive surgical procedure. After taking adequate tissue for HPE, perfect 
hemostasis was achieved and no drain was kept. 
Role of FNAC in diagnosing sarcomas are limited. FNAC will be done for suspected 
recurrence after surgery and to diagnose sarcomas which are situated in deeper plane 
in trunk and abdomen. This is because the tissue material that we are getting through 
FNAC is inadequate to grade and subtype the tumour, which is essential in deciding 
its prognosis and choosing adjuvant therapy. After histological confirmation , staging 
work up will be done by using conventional radiographs, CT and MRI for local 
disease , And radiographs and CT for distant metastasis.  
After complete evaluation, the extremities soft tissue sarcomas with distal metastasis,  
inoperable lesions,  medically unfit or not willing for surgery were referred to 
palliative treatment. Other patients were taken for surgery after proper counselling. 
 
 
 
 
 
 
 
 
 
 Department protocol for management of extremity soft tissue sarcomas: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EBRT – External Beam Radiotherapy 
History and physical examination 
                            Chest radiography 
CT /MRI  of primary site 
Biopsy – Core Vs Incisional 
Determine prognosis based on histological type 
i d d ti t
Low Grade High Grade 
Functional sparing 
complete excision  
Functional sparing 
complete Excision 
Negative 
Margin 
Microscopic 
positive margin 
> 1cm margin <1cm margin or 
microscopic margin 
Post op EBRTNo adjuvant 
therapy 
< 5cm in size > 5cm in size Post op EBRT
No adjuvant 
therapy 
Post op EBRT 
 
 
      Guidelines for Limb sparing resection: 
1. No major neurovascular tumour involvement.  
2. Wide resection of affected part with a normal cuff tissues in all direction. 
3. En bloc removal of all previous biopsy sites and potentially contaminated tissue 
4. Adequate motor reconstruction. 
Contraindications for limp sparing surgery 
1. major neurovascular involvement 
2. pathologic fracture 
3. inappropriate biopsy site 
4. Gross infection 
5. skeletal immaturity 
6. extensive muscle involvement 
Limb sparing surgery were done to two group of  patients. The first group were 
those who  underwent  primary surgery in our institution. The second group of 
patients to whom the primary surgery was done elsewhere and referred with local 
recurrence. They were restaged and those with distant metastasis were referred for 
palliative treatment. Other were underwent surgical treatment either limb sparing 
procedure or amputation which were decided by above mentioned factors . Those 
patients who were not fulfilling the above guidelines , underwent amputation.  All 
the groups were studied and registered individually 
 
 
 
   Follow up: 
 First  year    every month 
 Second year    every second month 
 Third year    every third month 
      4&5 th years                                        every six month 
      6 th year onward                                 annually 
   On every follow up: 
1. Patient had full clinical examination 
(On basis of suspicion of recurrence or metastasis or otherwise annually) 
2. X-ray chest PA view 
3. Radiograph of part concerned if necessary 
4. For suspected lesion in chest, CT chest was suggested 
5. For suspected local recurrence Trucut Biopsy /  FNAC ± MRI was done 
Death rate : Documented death rate has been taken for this study. But many 
patients lost their follow up. Here, the projected death may not reflect the actual 
death rate. 
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RESULTS AND OBSERVATION 
Between Jan’ 2001 – Dec’ 2005, about 107 patients of extremity soft tissue sarcomas 
were treated in our institution. After metastatic work up, about 41 patients were found 
to be with distal metastasis and two patients were at inoperable stage due to extensive 
soft tissue involvement at critical anatomical site. These 43 patients were referred for 
palliative chemoradiotherapy. Others underwent multimodality treatment. 
OBSERVATION 
I. SEX DISTRIBUTION 
                            Sixty cases were male and forty seven cases were female. 
                                                           Male : Female ratio  is 1.3 : 1. 
II. ANATOMICAL DISTRIBUTION: 
        
         Out of 107 cases,     Upper limb – 42 cases (39.3%) 
    Lower limb – 65 cases (60.7%) 
                          Thigh alone – 42 cases (39.3%) 
 
 
Colum
n 1
THIGH
LL
0
20
40
60
80
100
SITES
N
O
 O
F 
C
A
SE
S
UL
 
III   HISTOLOGICAL TYPES OF SOFT TISSUE SARCOMAS 
MPNST
16%
LIP SAR
27%
MFH
40%
SYN SAR
12%
OTHERS
5%
MPNST
LIP SAR
MFH
SYN SAR
OTHERS
MPNST-Malignant peripheral nerve sheath tumour,LIP SAR-Liposarcoma 
MFH-Malignant fibrous histiocytoma,SYN SAR-Synovial sarcoma. 
 
 
 
 
 
Malignant  fibrous  histiocytoma              n - 43 (40.2%) 
Liposarcomas                                            n - 29 (27.1%)  
MPNST                                                     n - 17 (15.9%) 
Synovial sarcoma                                      n - 13 (12.1%) 
Others                                                        n  - 5 (4.7%) 
 
 
IV AGE DISTRIBUTION 
1. Malignant fibrous histiocytoma   n - 43 
     
 
 
 
 
 
 
Age in years Cases 
20-29 1 
30-39 5 
40-49 2 
50-59 11 
60-69 2 
70-79 Nil 
80-89 1 
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2. Liposarcoma   n – 29 cases 
 
< 20 yrs 4 
20-29 9 
30-39 4 
40-49 4 
50-59 4 
60-69 4 
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3. Malignant Peripheral Nerve Sheath Tumours 
 
                                                 n – 17 cases 
 
< 20 yrs 2 
20-29 4 
30-39 7 
40-49 2 
50-59 2 
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4.Synovial Sarcoma n -13 cases 
 
< 20 yrs 4 
20-29 9 
30-39 4 
40-49 4 
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No. of cases
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Age in years
Age in Years
6.Others  n – 5 cases. 
 
 
 
IV TREATMEMT  STATISTICS 
 
Limb sparing surgery Total number of patients 
underwent surgery Primary 
surgery 
Reresection 
For local 
recurrence 
Amputation 
                     
                    64 
       
        25 
       
        31 
                  
                     8 
 
 
a.     Twenty eight cases were  underwent primary surgical treatment in our 
institution . 
Wide local excision                   -              20 cases (71.4%) 
Compartmental resection          -                4 cases 
Rotation plasty                          -                1 case 
         Total limb sparing surgery        -               25 cases (89.2%) 
   Amputation                 -                 3 cases (10.8%)  
b.     Second surgery for recurrence Soft tissue sarcoma  primarily operated 
elsewhere  
                                    Total no. of cases                      -               36  
                                    Wide local excision                   -               25(69.4%) 
   Compartmental resection           -                6 
   Total (limb sparing surgery)      -               31 (86.1% ) 
 
 
   Amputation      -                 5 (13.9%) 
                                    
                                    Over all  Limb sparing surgery -                56 (87.5%) 
                                    Amputation                               -                   8 (12.5%) 
LSS
87%
AMP
13%
LSS
AMP
LSS- Limb sparing surgery          AMP- Amputation 
 
V  RECURRENCE RATE 
 
After surgical treatment six patients developed local recurrence of which two(7.1%) 
from the group who underwent primary resection, four(11.1%) from the group who 
underwent re-resection for local recurrence. 
All the local recurrence were in patient who underwent limb sparing surgery. No 
amputee developed local recurrence. Local recurrence rate is 9.4%. 
        Local recurrence After primary surgery in  After re-resection  
 
 
        our institute (first surgery elsewhere) 
                6(9.4%)        2(7.1%)                     4(11.1%) 
 
METASTASIS 
 
Ten patients developed distant metastasis. All were seen in lung (100%). Seven 
patients who underwent limb sparing surgery and three patient who underwent 
amputation developed pulmonary metastasis.  Two patients developed both local 
recurrence and pulmonary metastasis simultaneously. All metastasis and local 
recurrence developed within 2 years of initial diagnosis. All were the high grade 
tumour. 
 
DEATH 
 
Eleven patients has been document as died in hospital due to soft tissue sarcoma in 5 
years follow up with mean follow up of 29 months of which 9 patients were with 
distal metastasis (81.8%). Many patients lost for follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Soft tissue sarcomas are rare tumour. Since our institution is a tertiary centre and has 
well established oncology department, we are treating a significant number of soft 
tissue sarcomas. An analysis of population based data from Connectiout suggest 
increased  incidence in both men and women, with a greater increase in women. This 
study shows increase number of soft tissue sarcomas in both male and female with 
minimal male preponderance. (M:F ration 1.3:1). 
 
In MSKCC series shows mean age of soft tissue sarcoma occurrence as 51 years with 
range of 16-93 years and most of them are seen in sixth decade. In this review shows 
that age distribution range of 13-80 years with mean age of 39.1 years. Majority of 
cases were seen in fifth decade (40-49) years, especially malignant fibrous 
histiocytoma, the most common soft tissue sarcoma which is reported as more 
common in seventh decade. But in this review, MFH is common in fifth decade.  
 
Lawrence et al, in his series found as soft tissue sarcomas in upper extremity as 30%, 
and lower extremity as 70%. In this study, we found upper extremity soft tissue 
 
 
sarcoma were about 39.3% and lower extremity as 60.7% Thigh is most common site 
for soft tissue sarcoma. This has been supported by this study which found about 
39.3% of extremity soft tissue sarcoma seen in thigh region. 
 
In a study conducted in MCH U.S(1994) showed malignant fibrous histiocytoma as 
most common soft tissue sarcoma (21.9%) followed by liposarcoma (16.0%) and 
MPNST(9.6%). In this review shows most common extremity soft tissue sarcoma is 
MFH (40.2%) followed by LPS (27.1%). Surprisingly MPNST accounted as (15.9%). 
By comparing both studies there is increased incidence of MFH and MPNST in our 
region. Synovial sarcoma is common among young adult. In this study shows most of 
the synovial sarcomas were seen in second and third decade (76.9%).  
 
 
 
Study series Total number of 
patients operated  
Limbsparing             
surgery 
Amputations 
Maghert et al 413 388 (94%) 25 (6%) 
Sluga et al 130 116(89.2%) 14(10.8%) 
Our study results 64 56 (87.5%) 8 (12.5%) 
 
 
Before 1991, 90% of extremity soft tissue sarcoma were treated by amputation. After 
1990, with better knowledge about biology of soft tissue sarcoma,  availability of 
 
 
imaging modality, multimodality of treatment, improvement limb reconstruction 
technique and improved rehabilitation facilities, now about  90% of extremity soft 
tissue sarcoma are treated by limb salvage procedure. In this review study., out of 28 
newly diagnosed soft tissue sarcoma, limb sparing surgery was done in 25 cases 
(89.2%). Where as amputation was done in 3 cases (10.7%). In recurrence soft tissue 
sarcoma (36 cases)  limb sparing surgery was achieved in 31 cases (86.1%). 
Amputation was done in 5 cases (13.8%). The minimal increase in amputation in the 
group with Re-resection were due to unplanned previous surgery like unknowingly 
tumour was  removed as benign or improper biopsy procedure or intralesional / 
intracapuslar excision. 
 
This led to difficulty in planning for second limb sparing procedure. In spite of this 
overall limb salvage rate of 87.5% was achieved. This study confirms the influence of 
surgical margin achieved in development of local recurrence and stress the 
importance of proper planning of primary surgery to minimize local recurrence . 
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STUDY 
SERIES 
    
Wirbel et al 
  
Enneking et al 
   
Sluga et al 
Our study  
results 
Local 
recurrence after 
limb sparing 
surgery. 
 
          9.3 % 
 
           5% 
 
      2.3% 
 
           9.4% 
 
 
 
 
                        Wirbal et al, his series showed local recurrence rate of 9.3% after wide 
local excision with margin negative specimen and 28.5% after marginal margin 
resection. Simon and Enneking et al, in their series, found 5% local recurrence after 
negative margin and 89% of local recurrence after positive margin. In this study, 
After surgical treatment, six patients (9.4%) developed local recurrence of which two 
(9.1%) patients after primary resection. Four(11%)  patients  after re-resection 
developed local recurrence. This definitely shows the increase in local recurrence in 
re-resection group was due to unplanned first surgery which made difficulty in second 
limb sparing surgery. Moreover 5 out of 6 local recurrence were margin positive 
cases (83.3%). 
 
                    Lung is the commonest site for distal metastasis extremity sarcomas. In 
this study ten patients developed distal metastasis All of them were pulmonary 
metastasis (100%). A study about extremity soft tissue sarcoma showed isolated lung 
metastasis as 70%, multiple metastasis as 5%. More than 60% of metastasis are found 
within 2 years. In this study, All lung metastasis were found with mean follow up of 
29 months. Three metastasis were seen after amputation., which shows local control 
of soft tissue sarcoma does not alter the metastatic rate. By this, it is evident that local 
control of disease and metastasis are two separate entity which are individually 
determined by stage of the tumours. Achieving complete local control of disease will 
not alter the chance of distant metastasis. 
 
 
 
Documented death of 11 cases were reported of which nine were with metastatic 
disease. It is evident as metastasis shorten the overall survival rate. Since many 
patients lost their follow up , this death rate is not reflecting the real picture of overall 
survival in soft tissue sarcomas of extremity after multimodality treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
This retrospective review on “Limb salvage in extremity soft tissue sacomas” for  
five years period shows: 
 Occurrence of limb soft tissue sarcomas has shifted one decade Iin our region 
earlier than literature  evidence. More number of soft tissue sarcoma seen in 
younger age with minimal male  preponderance 
 Histologically, malignant fibrous histiocytoma is the most common extremity 
soft tissue sarcoma, followed by liposarcoma and occurrence of MPNST 
seems to be increased in our region 
 Anatomically lower limb is common site, especially thigh is the most common 
site for limb sarcomas 
 Due to better knowledge about soft tissue sarcoma, availability of imaging 
modality and multimodality treatment and improvement in limb 
 
 
reconstruction technique, Limb salvage procedure is achievable in about 90% 
of extremity soft tissue sarcomas. 
 Local recurrence after limb sparing surgery is only 9.4% and shows success of 
limb sparing technique. 
 Local recurrence are higher in re-resection group due to unplanned previous 
surgery which make the second surgery difficult to achieve limb salvage. 
 First surgery is the best surgery as far as limb salvage and local control of 
disease concerned. 
 Ideally biopsy should be done by the same surgeon who is going to do 
definitive surgical procedure 
 Distant metastatic potential is not influenced by successful local control  
 Local recurrence and distant metastasis are determined by tumour size, grade 
and plane of swelling as  individual factor 
 .Lung is the most commonest site of distal metastasis for extremities soft 
tissue sarcoma. 
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ANNEXURE 
 
 
 
   
 
 
 
 
 
 
  PROFORMA 
 
a. Particulars of patient 
i. Name 
ii. Age 
iii. Sex 
iv. Occupation 
v. Religion 
vi. Residence 
 
 
vii. In patient No: 
viii. Date of Admission 
ix. Date of surgery 
x. Date of discharge 
b. Complaints and Duration 
i. Swelling 
ii. Ulceration 
iii. Pain 
iv. Numbness 
v. Paresthesia 
vi. Fever 
vii. Fainting 
viii. Appetite 
ix. Loss of weight 
x. Alteration in function of limb 
xi. Cough 
xii. Haemoptysis 
xiii. Bone pain 
xiv. Jaundice 
xv. Paralysis 
xvi. Similar swelling 
xvii. Conclusion 
xviii. Fracture 
 
 
III  Past history  
1. Tuberculosis  
2. Diabetes mellitus 
3. Hypertension 
4. Jaundice 
5.  Burns  
6.  Radiation  
7.  Trauma  
8.  Previous surgery  
9.  any other malignancy 
 
IV  Personal History 
1. Dietary Habits 
2. Smoking 
3. Alcoholism 
 
V    Occupational History 
        Employment in dye industry 
 
VI    Family History 
        Similar illness in any other members of I relatives 
 
VII  Physical Examination 
 
 
1. General Examination 
a. Nutritional status 
b. Anaemia 
c. Jaundice 
d. Pedal edema 
e. Dyspnoea 
f. Clubbing 
g. Generalized / significant lymph adenopathy 
2. Local examination 
a. Location of tumour in relation to known anatomical land marks 
b. Characteristics of tumour 
c. Involvement of adjacent structure 
d. Confinement to anatomical compartment 
e. Distal neurovascular deficit 
f. Near by joint movement 
3. Nodal status 
a. Not involved 
b. Involved –Ipsilateral / Bilateral, features of lymph nodes 
4. Distant metastasis 
5. Clinical diagnosis (includes clinical staging) 
VIII  Histological features : type / subtype grade 
IX  Investigations 
X Treatment planned 
 
 
XI Outcome 
XII Remarks 
XIII Follow up 
 
 
 
 
 
 
 
 
 
 
 
 
                                             
 
 
                                            MASTER CHART 
 
NEW CASES  –  UPPER LIMB SOFT TISSUE SARCOMAS 
 
 
 
S.No NAME 
AGE/S
EX 
I.P No 
ANATMOMICA
L SITE 
HISTOLOGICAL 
TYPE/ GRADE 
SURGERY REMARKS 
1 RAJESHKUMAR 28/M 808018 
RT. SCAPULAR 
REGION 
LIPOSARCOMA, LG WLE - 
2 ELANGO 45/M 801841 
LT SHOULDER 
AREA 
MFH, HG WLE - 
 
 
3 ARIVALAGAN 50/M 816443 RT FOREARM LIPOSARCOMA LG WLE - 
4 SHUBA 27/F 813081 LT ELBOW 
SYNOVIAL 
SARCOMA 
AE AMPUTATION - 
5 MURUGAN 41/M 813776 RT FOREARM MFH, HG AE AMPUTATION M/D 
6 MUSTAFA 80/M 783116 
RT ELBOW 
REGION 
MFH WLE - 
7 GNANAROSE 27/F 726478 RT FOREARM DFSP, LG WLE R 
8 MANOHARAN 42/M 728127 RT ARM MFH, HG WLE - 
9 JAYALAKSHMI 40/F 710487 LT ARM MFH, HG WLE - 
10 PALANI 34/M 719263 RT ARM MPNST 
WLE WITH 
ROTATION PLASTY 
- 
11 KUMAR 47/F 719667 LT. FOREARM 
SYNOVIAL 
SARCOMA 
WLE - 
12 RADHIKA 21/F 716465 RT. FOREARM MPNST WLE - 
M-Metastasis, R-Recurrence, D-Died. 
 
 
 
 
 
 
 
 
                                                NEW CASES LOWER LIMB 
 
 
 
S.No NAME 
AGE/S
EX 
I.P No 
ANATMOMICA
L SITE 
HISTOLOGICAL 
TYPE/ GRADE 
SURGERY REMARKS 
1 SAMPATH 30/M 778021 
RT. SILIAC 
REGION 
MPNST, HG 
RT. INTERNAL 
HEMIPELVECTOMY 
- 
2 MURALI 15/M 774057 LT  THIGH LIPOSARCOMA, HG WLE M 
3 SELVAKUMAR 15/M 775264 LT THIGH SYNOVIAL LG WLE - 
 
 
4 CHITTU 40/F 789391 RT THIGH MFH, HG WLE - 
5 ROYAMMAL 55/F 787956 LT THIGH MFH, HG WLE - 
6 PADMAVATHY 40/F 794205 LT THIGH MPNST, HG WLE - 
7 MANI 56/M 797454 LT THIGH MFH, HG 
HAMSTRING  
COMPARTMENTAL 
RESECTION 
- 
8 SRINIVASAN 36/M 786791 LT THIGH MPNST, HG HAMSTRING C.R M/D 
9 MUNIAMMAL  39/M 726610 LT LEG 
SYNOVIAL 
SARCOMA 
LT AK AMPUTATION - 
10 MARIAPPAN 21/M 742111 RT THIGH LIPOSARCOMA, LG WLE - 
11 SHAKTHI 36/M 752105 LT THIGH LIPOSARCOMA, LG WLE - 
12 RUKMANI 56/F 756341 LT THIGH MFH, HG WLE R 
13 MUTHULAKSHMI 55/F 753165 LT THIGH MFH, HG WLE - 
14 POONGODI 45/F 759635 RT THIGH MFH, HG WLE - 
15 GANDHIMATHI 36/F 766849 LT LEG 
SYNOVIALMFH, HG 
SARCOMA, HG 
WLE - 
16 RAJAN 62/M 776526 RT THIGH LIPOSARCOMA, HG ADDUCTOR C.R - 
M-Metastasis, R-Recurrence, D-Died. 
 
 
 
 
 
 
                       RECURRENCE SOFT TISSUE SARCOMAS – UPPER LIMB 
 
 
 
S.No NAME 
AGE/S
EX 
I.P No 
ANATMOMICA
L SITE 
HISTOLOGICAL 
TYPE/ GRADE 
SURGERY REMARKS 
1 SHANTHI 40/F 821745 RT ARM MFH, HG 
RT SHOULDER 
DISSARTICULATION 
M/D 
2 DHANALAKSHMI 45/F 821898 LT FOREARM MFH, HG AE AMPUTATION - 
3 
PURUSHOTHAMA
N 
27/M 824549 
LT ELBOW 
AREA 
MPNST, HG WLE - 
 
 
4 DHANALKSHMI 31/F 826617 LT ARM MPNST, HG WLE - 
5 BOOPATHY 34/F 89220 RT FOREARM MPNST, HG WLE M/D 
6 STELLAMANY 30/F 779394 RT ARM LIPOSARCOMA, LG WLE - 
7 MUNIAMAL 55/F 784074 
RT ELBOW 
REGION 
MFH, HG WLE - 
8 GANGAN 53/M 782128 LT ARM LIPOSARCOMA, LG WLE - 
9 JAYALAKSHMI 45/M 772979 RT FORE ARM MFH, HG WLE - 
10 RAMANI 17/F 781031 RT ARM 
SYNOVIAL 
SARCOMA 
WLE - 
11 DEVI 40/F 723141 RT ARM LIPOSARCOMA, HG WLE - 
12 MURUGESAN 45/M 720385 
LT ELBOW 
AREA 
MPNST, HG WLE - 
13 BALARAMAN 50/M 763953 
LT SCAPULAR 
REGION 
FIBROSARCOMA, 
HG 
LT SCAPULECTOMY - 
14 VIJAYAKUMAR 23/M 785040 RT FORE ARM LIPOSARCOMA, LG  WLE - 
M-Metastasis, R-Recurrence, D-Died. 
 
 
 
 
 
 
LOWER LIMB 
 
S.No NAME 
AGE/S
EX 
I.P No 
ANATMOMICA
L SITE 
HISTOLOGICAL 
TYPE/ GRADE 
SURGERY REMARKS 
1 SAMRUTHI 30/F 714355 
SACROGUTEA
L REGION 
LIPOSARCOMA, LG WLE - 
2 GOVINDAMMAL 51/F 818752 LT  THIGH MFH, HG WLE - 
3 ANJALAGAN 47/F 821643 RT THIGH MFH, HG ADD, C.R R 
4 SAMPATH 34/M 822587 LT THIGH MFH, HG 
LT H.P 
DISARTICULATION 
- 
5 KANJANA 19/F 827598 LT THIGH ANGIOSARCOMA 
WLE VASCULAR 
RECONSTRUCTION 
- 
 
 
6 LALITHA 19/F 827598 LT THIGH LIPOSARCOMA, HG ADDN C.R - 
7 RAMAPRIYA 28/F 814389 
RT 
POPLITHEAL 
FOSSA 
LIPOSARCOMA, HG WLE M/D 
8 ANITHA 21/F 815745 LT THIGH 
SYNOVIAL 
SARCOMA, HG 
WLE WITH INGUINAL 
BLOCK DISSECTION 
- 
9 RANJITH 15/M 765849 
RT GLUTEAL 
AREA 
LIPOSARCOMA, HG WLE D 
10 VADIVEL 18/F 762537 LT THIGH MPNST, HG WLE - 
11 PATCHIYAPPAN 29/M 772344 RT LEG MPNST, HG WLE M/D 
12 MURALI 16/M 724057 RT THIGH LIPOSARCOMA. LG HAMS. C.R - 
13 KAMALA 55/F 762102 RT THIGH MFH, HG WLE - 
14 KALIMUTHU 45/F 754196 RT LEG MFH, HG RT AE AMPUTATION - 
15 SUKUMAR 25/M 762994 LT LEG 
SYNOVIAL 
SARCOMA, HG 
WLE - 
16 BALAJI 18/M 760443 LT FOOT 
SYNOVIAL 
SARCOMA, HG 
SYMES AMPUTATION - 
17 SATHESH 22/M 760669 
LT 
POPLITIEAL 
FOSCA 
MFH, HG WLE M/D 
18 BHARATHI 25/F 737551 LT LEG MPNST, HG WLE - 
19 VIJAYALAKSHMI 32/F 737742 LT LEG MPNST, HG POSTERIOR C.R R/M/D 
20 DEVI 40/F 723141 RT THIGH MFH, HG ANTERIOR C.R - 
21 NAGARAJ 35/M 720654 RT LEG 
SYNOVIAL 
SARCOMA, HG 
WLE - 
22 MURUGESAN 45/M 720585 LT THIGH MFH, HG C.R - 
LG- low grade, HG- high grade, WLE- wide local excision, CR- compartmental 
resection. M-Metastasis, R-Recurrence, D-Died. 
          SOFT TISUE SARCOMAS WITH DISTANT METASTASIS  
 
S.No NAME 
AGE/S
EX 
I.P No 
ANATMOMICA
L SITE 
HISTOLOGICAL 
TYPE/ GRADE 
METASTATIC SITE 
1 PRAKASH 37/M 701928 LT THIGH LIPOSARCOMA, LG LUNG 
2 SASIKALA 59/F 703552 LT GROIN MPNST, HG LUNG 
3 RUKMANI 48/F 704604 RT THIGH MFH, HG LUNG 
4 RADHIKA 40/M 706465 RT THIGH MFH, HG LUNG 
5 PURUSOTHAMAN 56/F 708948 LT ARM LIPOSARCOMA, HG LUNG 
 
 
6 BAKYALAKSHMI 55/F 708862 LT ARM MFH, HG LUNG 
7 BADHAR 25/F 708860 RT ARM MPNDT LUNG 
8 MANAVALAN 56/M 712609 RT THIGH MFH, HG LUNG/SKULL BONE 
9 PLANIESHWAR 60/F 712884 RT THIGH LIPOSARCOMA, HG LUNG 
10 SHAHANA 28/F 714624 
RT GLUTEAL 
REGION 
LIPOSARCOMA, HG LUNG 
11 IYYANAR 62/M 724530 
RT GLUTEAL 
REGION 
MFH, HG LUNG 
12 MANIKANDAN 43/M 724896 RT THIGH MFH, HG LUNG 
13 MANAVALAN 38/M 726849 RT THIGH MFH, HG LUNG 
14 VALARMATHY 32/F 728721 RT FOREARM LIPOSARCOMA, HG LUNG 
15 SIVAKUMAR 40/M 791346 RT THIGH MFH, HG LUNG 
16 JAYALAKSHMI 52/F 72032 LT FOREARM MFH, HG LUNG 
17 ROSSIAMMAL 60/F 751278 LT THIGH LIPOSARCOMA, HG LUNG 
18 PARAMESWARI 43/F 751014 LT LEG LIPOSARCOMA, HG LUNG 
19 MURUGAN 48/F 752285 
RT SHOULDER 
AREA 
MFH, HG LUNG 
20 SUKUMAR 47/M 752994 
RT GLUTEAL 
REGION 
LIPOSARCOMA, HG LUNG/LIVER 
21 SENTHILKUMAR 34/M 754219 RT LEG MFH, HG LUNG 
22 KAVIKARASI 55/F 756952 LT FOREARM 
ANGIOSARCOMA, 
HG 
LUNG & LIVER 
23 RAJAMANICKAM 65/M 761391 RT THIGH MGH, HG LUNG 
24 THUKKARAM 58/M 762915 LT GROIN LIPOSARCOMA, HG INOPERABLE 
25 NALLATHAMBI 42/M 760349 RT ARM LIPOSARCOMA, HG LUNG 
26 ANNAMMAL 45/F 763596 RT THIGH LIPOSARCOMA, HG LUNG 
27 VADIVEL 45/M 762537 
LT ELBOW 
AREA 
MFH, HG LUNG 
28 LATHA 43/F 759213 LT THIGH MFH, HG LUNG 
29 PATCHIYAPPAN 38/M 772344 LT LEG MFH, HG LUNG 
30 KARTHIK 24/M 784401 RT ELBOW 
SYNOVIAL 
SARCOMA, HG 
LUNG 
31 DIVYA 29/FF 786434 RT LEG LIPOSARCOMA, HG LUNG 
32 PRAKASH 39/M 783094 LT FOREARM MFH, HG LUNG 
33 SHINEE 29/F 791070 LT THIGH LIPOSARCOMA, HG LUNG/SPINE 
34 LINGAM 60/M 798932 RT ARM MFH, HG LUNG 
35 BALAMURUGAN 48/M 796903 RT THIGH MFH, HG LUNG 
 
 
36 SHANKAR 39/M 795041 LT ELBOW 
SYNOVIAL 
SARCOMA, HG 
LUNG 
37 MOHAN 52/M 800492 LT THIGH MPNST, HG INOPERABLE 
38 RAMESH 43/M 802859 RT LEG MFH, HG LUNG 
39 VIJAY 18/M 805070 RT THIGH 
SYNOVIAL 
SARCOMA, HG 
LUNG 
40 BALARAMAN 39/M 813953 LT THIGH MFH, HG LUNG 
41 ALAGANBAN 48/M 817548 LT ARM MFH, HG LUNG 
42 KANNAN 21/M 822003 LT LEG 
SYNOVIAL 
SARCOMA 
LUNG 
43 SATHIYA 27/F 823605 
RT SHOULDER 
REGION 
MPNST, HG LUNG 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 illustrate , A 58 yrs old man , a case of malignt fibrous histiocytoma 
underwent adductor compartmental resection. 
 
 
 
Figure illustrate, A 32 yrs old lady a case of MPNST (recurrence) Rt leg underwent 
post compartmental resection. 
 
 
 
 
 
 
 
 
 
This figure illustrate, A 36 yrs old man , a case of  MPNST Lt thigh underwent 
Hamstring compartmental resection. 
Sciatic nerve
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure illustrate, A  40yrs old lady , a case of Malignant fibrous histiocytoma 
Rt arm near  elbow joint underwent AmputoResection  and Rotationplasty. 
 
 
 
 
 
 
 
 
This figure illustrate, A 34 yrs old lady , a case of  MPNST Rt forearm , underwent 
Wide        local excision with median nerve.   
 
 
 
This figure illustrate A 36yrs old man , a case of Liposarcoma Lt thigh underwent 
Wide local excision. 
 
 
f 
 
This figure illustrate, A 40yrs old lady , acase of High grade Liposarcoma Rt arm 
With local recurrence underwent wide local resection with post operative 
radiotherapy. 
 
 
 
 
 
 
 
 
 
 
 
This figure illustrate A 55yrs old man a case of High grade malignt fibrous 
histiocytoma underwent multimodality treatment presented post radiotherapy 
complication..   
 
 
 
 
 
 
 
 
 
This figures illustrate, A 45yrs old man ,a case of recurrent Malignant fibrous 
histiocytoma Rt thigh underwent Wide local excision . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure illustrate, A 56yrs male a case of Malignant  fibrous histiocytoma Lt thigh 
posterior compartment, underwent Hamstring compartmental resection. 
 
 
       Sciatic nerve 
